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Streszczenie 
Przedstawiona praca doktorska dotyczy mobilizacji komórek macierzystych do uszkodzonej 
tkanki mięśniowej. Opisane w niej badania koncentrowały się na opracowaniu metod 
prowadzących do zwiększenia zdolności zarówno endogennych jak i egzogennych,  
tj. przeszczepianych komórek macierzystych do udziału w regeneracji mięśni szkieletowych 
myszy. Dotyczyły także poznania mechanizmów molekularnych, jakie towarzyszą zarówno 
migracji jak i różnicowaniu tych komórek. 
Mięśnie szkieletowe, obok tkanek budujących skórę, są jedną z tkanek najbardziej narażonych 
na urazy. Z tego powodu ich prawidłowa regeneracja jest niezmiernie istotna dla prawidłowego 
funkcjonowania organizmu. Mięśnie szkieletowe składają się z wielojądrzastych włókien 
mięśniowych, które mają zdolność do kurczenia się, co stanowi podstawę ich funkcjonowania. 
W odpowiedzi na uraz uszkodzone włókna mięśniowe zostają usunięte przez napływające 
makrofagi, a następnie zastąpione przez nowe włókna [1]. Nowe włókna mięśniowe powstają 
dzięki fuzji jednojądrzastych komórek, które tworzą najpierw wielojądrzaste miotuby, 
„dojrzewające” następnie we włókna mięśniowe posiadające setki jąder komórkowych.  
W przypadku regeneracji mięśni kluczowe są więc komórki progenitorowe zdolne do 
różnicowania miogenicznego i fuzji, a co za tym idzie odtwarzania nowych włókien 
mięśniowych. W warunkach fizjologicznych pulę takich komórek tworzą komórki satelitowe, 
czyli komórki macierzyste mięśni szkieletowych, z których w wyniku podziałów komórkowych 
powstają zdolne do fuzji mioblasty [2]. Zapewniają one bardzo wydajną regenerację. Jednak w 
przypadku rozległych uszkodzeń, procesu starzenia, cukrzycy, nowotworów, a także chorób 
mięśniowych, np. dystrofii, naprawa tkanki nie przebiega prawidłowo. Konsekwencją 
nieprawidłowej regeneracji może być utrata funkcjonalności mięśni i ich zwiększona podatność 
na ponowne uszkodzenia [3]. Jedną z potencjalnych form wspomagania regeneracji mięśni 
szkieletowych mogłaby być terapia komórkowa polegająca na mobilizacji własnych komórek 
macierzystych lub na podawaniu pacjentowi egzogennych komórek macierzystych - 
izolowanych z tkanek pacjenta lub dawcy [4]. Komórki takie powinny mieć zdolność do 
uczestniczenia w odtwarzaniu włókien mięśniowych. Jedną z największych przeszkód  
w skutecznym zastosowaniu komórek macierzystych we wspomaganiu regeneracji mięśni 
szkieletowych jest ograniczona zdolność tych komórek do migracji w obrębie uszkodzonego 
mięśnia. Podanie komórek, które nie są zdolne do migracji skutkuje ich wyłącznie lokalnym 
udziałem w rekonstrukcji, a to nie wpływa na poprawę funkcjonowania mięśnia [5, 6]. 
Istnieje wiele populacji komórek macierzystych, które mogłyby zostać wykorzystane do 
wspomagania regeneracji. W prowadzonych przeze mnie badaniach, analizowałem trzy rodzaje 
takich komórek - pluripotencjalne zarodkowe komórki macierzyste (ESC, ang. Embryonic 
Stem Cells), multipotencjalne komórki macierzyste szpiku kostnego (BMSC, ang. Bone 
Marrow Stem Cells) oraz komórki satelitowe, czyli unipotencjalne komórki macierzyste mięśni 
szkieletowych. Wybór ten był podyktowany różnicami w potencjale miogenicznym tych 
komórek, czyli możliwością różnicowania w mioblasty i włókna mięśniowe, a także różnicami 
w ich zdolności do migracji i zasiedlania uszkodzonych mięśni szkieletowych [7, 8, 9]. 
W moich badaniach analizowałem rolę cytokiny Sdf-1 (ang. Stromal derived factor - 1)  
w mobilizacji komórek macierzystych zdolnych do uczestniczenia w regeneracji mięśni 
szkieletowych. W warunkach fizjologicznych cytokina ta jest produkowana w tkance  
w odpowiedzi na hipoksję, czyli obniżone stężenie tlenu, będące konsekwencją uszkodzenia. 
Jest ona chemoatraktantem dla komórek mających na swojej powierzchni receptor Cxcr4 
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(Cxcr4+). Receptor ten eksprymują komórki układu odpornościowego oraz wiele typów 
komórek macierzystych [10]. W prowadzonych badaniach postawiłem hipotezę, że 
mobilizowane przez Sdf-1 do regenerującego mięśnia endogenne i egzogenne komórki 
macierzyste mogą uczestniczyć w rekonstrukcji uszkodzonej tkanki.  
Aby zweryfikować powyższą hipotezę analizowałem regenerację mięśni myszy pozbawionych 
funkcjonalnych alleli genu Pax7 (Pax7-/-). Myszy Pax7-/- charakteryzuje złożony fenotyp, 
jednak z punktu widzenia prowadzonych przeze mnie doświadczeń najistotniejsze jest to, że 
ich mięśnie cechuje prawie całkowity brak komórek satelitowych. Dzięki temu mogłem 
analizować regenerację zachodzącą przy istotnym niedoborze komórek, które w warunkach 
fizjologicznych odpowiedzialne są za odbudowę tej tkanki. W trakcie prowadzonych 
doświadczeń podawałem myszom podskórnie cytokinę G-CSF (ang. Granulocyte Colony 
Stymulating Factor) powodującą uwolnienie ze szpiku kostnego do krwioobiegu komórek 
macierzystych. Następnie uszkadzałem mięśnie szkieletowe, do których po dobie podawałem 
roztwór chemokiny Sdf-1, która stymuluje napływ komórek z receptorem Cxcr4,  
m.in. komórek macierzystych szpiku kostnego. Wykazałem, że Sdf-1 mobilizuje do 
uszkodzonego mięśnia komórki Cxcr4+ syntetyzujące dodatkowo marker CD34, a więc 
komórki macierzyste ze szpiku kostnego. Wykazałem, że efektem podawania Sdf-1  
i mobilizacji komórek jest wzrost masy zrekonstruowanego mięśnia z jednoczesnym 
zmniejszeniem stopnia jego zwłóknienia - czyli ograniczenie powstawania tkanki łącznej. 
Wyniki te udowodniły, że zastosowanie G-CSF i Sdf-1 może stanowić skuteczny sposób na 
wspomaganie regeneracji mięśni szkieletowych w przypadkach niedoboru komórek 
satelitowych.  
Fuzja komórek jest obok migracji kluczowym procesem zachodzącym podczas regeneracji 
mięśni szkieletowych. Przebiega ona z udziałem transbłonowych białek adhezyjnych. 
Postawiłem hipotezę, że zmiany w poziomie tych białek mogą przekładać się na zdolność 
komórek macierzystych do migracji i fuzji z mioblastami. Wykazałem, że Sdf-1 zwiększa 
poziom białka adhezyjnego CD9 w ESC i BMSC. Udowodniłem również, że mechanizm 
wzrostu poziomu CD9 w odpowiedzi na Sdf-1 jest zależny od pobudzenia receptora Cxcr4. 
Aby sprawdzić, czy wzrost poziomu CD9 wpływa na zdolność do fuzji badanych komórek  
z komórkami mięśniowymi, przeprowadziłem hodowlę mieszaną, w trakcie której hodowałem 
mioblasty z badanymi komórkami tj. BMSC bądź ESC. Analizowałem komórki kontrolne oraz 
takie, które uprzednio traktowałem Sdf-1. Mioblasty fuzjując ze sobą tworzą wielojądrowe 
miotuby. Jeżeli badane komórki mają zdolność do fuzji to wspólnie z mioblastami będą tworzyć 
hybrydowe miotuby. Częstość, z jaką powstają takie miotuby odzwierciedla potencjał 
badanych komórek do uczestniczenia w regeneracji mięśni szkieletowych. Wykazałem, że Sdf-
1 zwiększa zdolność BMSC do uczestniczenia w tworzeniu hybrydowych miotub. Analiza ESC 
wykazała natomiast, że komórki te mają bardzo ograniczoną zdolność do tworzenia 
hybrydowych miotub, jednak stymulacja Sdf-1 wpływa na ich zdolność migracji.  
Pod wpływem Sdf-1 migrują one lepiej w hodowli i zamiast formować agregaty (jak ma to 
miejsce w hodowli kontrolnej) lokalizują się wzdłuż miotub powstających z mioblastów.  
Wiedząc, że Sdf-1 wpływa na komórki macierzyste zarówno in vivo jak i in vitro stymulując 
ich migrację i fuzję postawiłem hipotezę, że Sdf-1 aktywuje wewnątrzkomórkowe ścieżki 
sygnalizacyjne związane z tymi procesami. Badałem również rolę receptorów dla Sdf-1, czyli 
Cxcr4 i Cxcr7 w omówionych procesach. W tym celu hodowałem in vitro mysie ESC, ludzkie 
mezenchymalne komórki macierzyste izolowane z galarety Whartona (MSC,  
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ang. Mesenchymal Stem Cells) i mioblasty pierwotne uzyskane z komórek satelitowych 
izolowanych z mięśni szkieletowych myszy. Aby sprawdzić, który z receptorów: Cxcr4 czy 
Cxcr7, jest zaangażowany w odpowiedź komórki na traktowanie Sdf-1 wykorzystałem technikę 
siRNA pozwalającą wyciszyć ekspresję badanych receptorów. Wykazałem, że zarówno ESC, 
MSC jak i mioblasty pierwotne migrują w gradiencie Sdf-1 w sposób zależny wyłącznie od 
receptora Cxcr4. Ponadto stymulacja Sdf-1 powoduje wzrost aktywności GTPaz Rac-1 oraz 
Cdc42, a więc czynników odpowiedzialnych za rearanżację cytoszkieletu aktynowego 
uczestniczącego w migracji komórek. Efekt ten jest również zależny wyłącznie od receptora 
Cxcr4. Wykazałem także, że stymulacja badanych komórek za pośrednictwem zarówno 
receptora Cxcr4 jak i Cxcr7 powoduje wzrost poziomu ufosforylowanej, a więc aktywnej, 
formy kinazy płytek przylegania (FAK, ang. Focal Adhesion Kinase). Aktywna forma FAK 
jest odpowiedzialna za tworzenie płytek przylegania, struktur niezbędnych w trakcie migracji 
komórek [Figura 1]. Analiza wykonana techniką mikromacierzy pozwoliła mi na określenie 
zmian w transkryptomie ESC: kontrolnych, stymulowanych Sdf-1 oraz poddanych wyciszeniu 
ekspresji receptorów Cxcr4 bądź Cxcr7. Wykazałem, że w ESC przekazywanie sygnału  
z udziałem receptora Cxcr4 wpływa na ekspresję i aktywność białek związanych przede 
wszystkim z migracją i adhezją, podczas gdy Cxcr7 reguluje ekspresję białek 
cytoszkieletowych (np. aktyny).  
 
Figura 1. Sdf-1 aktywuje 
migrację komórek poprzez: 
Zwiększenie aktywności 
GTPaz Rac1 oraz Cdc42. Jest 
to mechanizm zależny od 
receptora Cxcr4.  
Sdf-1 działając poprzez 
receptory Cxcr4 oraz Cxcr7 
zwiększa również aktywność 
kinazy płytek przylegania 
(FAK). 
 
W kolejnym etapie doświadczeń określiłem jak zmiany indukowane przez Sdf-1 wpływają  
na zdolność komórek do zasiedlania uszkodzonych mięśni i udział w ich rekonstrukcji. 
Mioblasty pierwotne oraz ESC stymulowane Sdf-1 i/lub takie, w których wyciszyłem ekspresję 
receptora Cxcr4 lub Cxcr7, przeszczepiałem do regenerującego mięśnia szkieletowego. 
Wykazałem, że ESC mają bardzo ograniczoną zdolność do zasiedlania mięśnia, jednak 
stymulacja Sdf-1 powoduje wydajniejszą migrację tych komórek wzdłuż włókien 
mięśniowych. Mioblasty podane do regenerującego mięśnia są zdolne do uczestniczenia  
w regeneracji, stymulacja Sdf-1 zwiększa tę zdolność, podczas gdy wyciszenie ekspresji 
receptora Cxcr4 istotnie ją ogranicza. Obniżony poziom receptora Cxcr7 nie wpływa  
na zdolność mioblastów do zasiedlania regenerującego mięśnia. 
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Podsumowując, wyniki dotychczas opublikowanych badań wskazują na możliwość 
potencjalnego wykorzystania Sdf-1 do wspomagania regeneracji mięśni szkieletowych, 
zarówno w przypadku mobilizacji komórek endogennych, jak i po przeszczepianiu komórek. 
Mechanizm działania Sdf-1 opiera się przede wszystkim na stymulacji migracji komórek,  
co wykazałem zarówno w układzie in vitro jak i in vivo. Po drugie Sdf-1 promuje fuzję komórek 
macierzystych z komórkami mięśni szkieletowych za pośrednictwem białka adhezyjnego CD9. 
Zatem, podanie Sdf-1 do regenerującego mięśnia szkieletowego poprawia jego regenerację, 
głównie za sprawą zwiększenia udziału komórek macierzystych w odtwarzaniu nowych 
włókien mięśniowych [Figura 2] 
 
Figura 2. Regeneracja mięśni szkieletowych. Poza komórkami satelitowymi, z których powstają 
mioblasty, również inne endogenne i egzogenne komórki macierzyste wykazują zdolność do 
uczestniczenia w regeneracji mięśnia. Chemokina Sdf-1 tworzy gradient, który mobilizuje komórki 
macierzyste do regenerującego mięśnia, przez co zwiększa ich zdolność do współtworzenia nowych 
włókien mięśniowych.    
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Summary 
Presented PhD thesis concerns mobilization of stem cells into damaged skeletal muscle. 
Described experiments are focused on the development of methods improving the ability  
of endogenous and exogenous stem cells to participate in muscle regeneration. Moreover, 
described studies allowed to define the molecular pathways underlying cell migration and 
differentiation. 
Skeletal muscle and skin tissues are among the ones that are frequently exposed to injury. Their 
regeneration must be efficient in order to secure proper functioning of organism. Skeletal 
muscles are composed of multinucleated fibers that are able to contract. In consequence  
of injury damaged fibers are removed by infiltrating macrophages and new fibers are formed  
to replace the damaged ones [1]. The new muscle fibers are formed by the cytoplasmic fusion 
of mononucleated precursor cells – myoblasts. Myoblasts fuse with each other to form 
multinucleated myotubes which mature to become fully functional muscle fibers containing 
hundreds of nuclei.  
Thus, in case of skeletal muscle regeneration myoblasts able to fuse and then recreate muscle 
fibers are the key players in this process. Under physiological conditions these cells result from 
the differentiation of satellite cells, i.e. skeletal muscle stem cells. Satellite cells guarantee  
an efficient regeneration [2]. However, in consequence of extensive damage, aging or as a result 
of some pathological conditions regeneration may be not efficient. As a result muscle can lose 
functionality and become more prone to the next damage [3]. Cell therapy is among  
the approaches aiming to improve muscle regeneration.  Such therapy could base on  
the administration of stem cells which are able to participate in muscle regeneration [4]. Among 
many complications associated with the transplantation of stem cells, which cause that the 
improvement of muscle regeneration is not sufficient, is poor migration ability of cells within 
the regenerating muscle. Such failure to migrate limits the regeneration only to the site of cells 
injection and thus has no impact on muscle function [5, 6].  
The are many populations of stem cells which could be tested as a tool to improve skeletal 
muscle regeneration. I decided to test three types of those cells: pluripotent embryonic stem 
cells (ESCs), multipotent cells isolated from bone marrow (BMSCs) and unipotent satellite cells 
isolated from the skeletal muscles. Thus, I selected cells which represent different myogenic 
potential and different ability to migrate [7, 8, 9]. 
Next, I focused at the role of Sdf-1 (Stromal derived factor -1) in stem cells migration and 
participation in muscle regeneration. Under physiological conditions Sdf-1 is produced  
in the response to hypoxia, which is one of the symptoms of tissue injury. Sdf-1 mobilizes 
migration of cells that express Cxcr4 receptor on their surface [10]. Among such Cxcr4+ cells 
are immune cells and also many types of stem cells. The hypothesis I tested stated that Sdf-1 
could mobilize stem cells that are characterized by the ability to undergo myogenic 
differentiation. 
To examine abovementioned hypothesis I tested whether endogenous stem cells could be 
mobilized to regenerating muscle. If mobilized cells would be able to participate in  
the formation of new muscle fibers, muscle regeneration should be improved. In these 
experiments I took advantage of mice lacking functional Pax7 gene (Pax7-/-). Pax7-/- mice are 
characterized by complex phenotype but the most important was severely limited number of 
satellite cells in Pax7-/- mice muscles.  Thanks to this I could analyze muscle regeneration 
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occurring in the absence of satellite cells. Importantly, I could also check if endogenous stem 
cells could replace lacking satellite cells. Thus, Pax7-/- mice were subcutaneously injected with 
Granulocyte Colony Stimulating Factor (G-CSF) which induces mobilization of stem cells from 
bone marrow to the bloodstream. Then skeletal muscle was injured and injected with Sdf-1 
what stimulated the infiltration of Cxcr4 positive cells, i.e. BMSCs. Further analyzes proved 
that Sdf-1 mobilized Cxcr4+ and CD34+ cells to the site of the injury. In consequence skeletal 
muscle mass was increased and fibrosis was decreased. These results indicate that Sdf-1 
together with G-CSF could be used as an effective way to improve skeletal muscle regeneration 
in case of satellite cells deficiency. G-CSF stimulates releasing of BMSC from bone marrow to 
the bloodstream then Sdf-1 acts as a chemoattractant stimulating stem cells migration to muscle.  
Migration of the cells is the key “element” allowing proper muscle regeneration. However, it is 
the cell fusion which is the most important aspect of muscle repair. This process bases on 
adhesion proteins expressed by fusing cells. Thus, I examine if Sdf-1 will have an impact  
on the level of adhesion proteins in stem cells. Importantly, Sdf-1 stimulation led to the increase 
in the level of CD9 tetraspanin in ESCs and BMSCs. To check if CD9 up-regulation has  
an impact on cells fusion I co-cultured these stem cells with myoblasts. Such co-cultures will 
result in the formation of the hybrid myotubes only if analyzed cells (e.g. ESCs or BMSCs) 
present the ability to fuse with myoblast. Thus, hybrid myotubes contains nuclei of myoblast 
and examined cells. The frequency of hybrid myotubes formation reflects potency of examined 
stem cells to participate in muscle regeneration. Sdf-1 increased the ability of BMSCs  
to participate in the formation of hybrid myotubes. This effect was associated with the  
up-regulation of CD9 expression. ESCs analysis revealed that these cells have limited ability  
to fuse with myoblasts. However, Sdf-1 stimulated these cells to migrate and localize along 
forming myotubes. In control cultures they remained aggregated. Finally, I proved that the 
mechanism of CD9 up-regulation in response to Sdf-1 based on a Cxcr4 receptor.  
Knowing that Sdf-1 influences stem cells both in vivo and in vitro and stimulates their migration 
and fusion I was decided to focus at intracellular pathways engaged in the migration. 
Simultaneously I studied which Sdf-1 receptors: Cxcr4 or Cxcr7 are involved in the regulation 
of cellular migration. Mouse ESCs, human MSCs and myoblasts derived from mouse satellite 
cells were examined in this study. Using siRNA technique I silenced expression of Cxcr4  
or Cxcr7 receptor in these cells. Next, I stimulated the cells with Sdf-1. I have shown that both 
ESCs, MSCs, and myoblasts migrate in a gradient of Sdf-1 in Cxcr4 but not Cxcr7 dependent 
manner. Moreover, Sdf-1 increased the activity of GTPases Rac1 and Cdc42, i.e. the factors 
participating in migration by influencing the reconstruction of actin cytoskeleton. Similarly, 
this effect depended on the Cxcr4 but not Cxcr7 receptor. Sdf-1 also increased the level of 
active Focal Adhesive Kinase (FAK). However, this phenomenon was both Cxcr4 and Cxc7 
dependent. FAK was also necessary for migration of tested cells [Figure 1]. Transcriptome 
analysis of control ESCs, those Sdf-1 treated, and those with Cxcr4 or Cxcr7 silenced showed 
that Cxcr4 regulates migration and adhesion pathways whereas Cxcr7 dependent signaling is 
important for expression of some cytoskeleton proteins (e.g. actin).  
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Figure 1. Sdf-1 stimulate 
migration of cell through: 
Increased the activity of GTPase 
Rac1 and Cdc42. The effect is 
dependent on Cxcr4 receptor. 
Sdf-1 increased the activity of 
Focal Adhesion Kinase (FAK) in 
Cxcr4 and Cxcr7 dependent 
manner. 
 
 
 
 
Finally, primary myoblasts and ESCs that were stimulated with Sdf-1, as well as those ones  
in that either Cxcr4 or Cxcr7 expression was silenced, were transplanted to regenerating skeletal 
muscle. Next, the ability of this cells to participate in muscle regeneration were examined. ESCs 
presented the limited ability to home within the muscle and did not participate in the myofiber 
formation. However, similarly as it was observed in in vitro cultures Sdf-1 stimulated these 
cells to migrate within regenerating muscle and localize along fibers. In case of myoblasts  
Sdf-1 stimulation increased their ability to fuse. Silencing of Cxcr4 significantly decreased this 
ability. Cxcr7 was not involved in this process.  
Summarizing, results of experiments that I performed during my PhD studies indicate that  
Sdf-1 could be used to improve skeletal muscle regeneration based on endogenous  
or exogenous stem cells. Sdf-1 not only stimulate migration but also cell fusion by increasing 
CD9 level. Both mechanism increase the ability of stem cells to participate in the reconstruction 
of new muscle fibers [Figure 2]. 
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Figure 2. Skeletal muscle regeneration. Myoblast derived from satellite cells participate in skeletal 
muscle reconstruction, but also endogenous and egzogenous stem cells characterized by myogenic 
potential can take part in myotube and fiber formation. Sdf-1 chemokine gradient mobilize stem cells  
to the side of injury and by this increase ability to participate in new muscle fiber formation.   
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Cel pracy 
 
Celem prowadzonych przeze mnie doświadczeń było opracowanie metod wspomagania 
regeneracji mięśni szkieletowych ssaków. Badaną przeze mnie metodą była indukcja migracji 
komórek macierzystych, które potencjalnie mogłyby uczestniczyć w procesie odtwarzania 
włókien mięśniowych w rekonstruowanej tkance. 
Postawiłem nadrzędną hipotezę, że chemokina Sdf-1 uczestniczy w mobilizacji komórek 
macierzystych do uszkodzonej tkanki. Napływające komórki są zdolne do wspomagania 
regeneracji mięśnia, co przekłada się na zwiększenie wydajności tworzenia nowych 
włókien mięśniowych. Weryfikowałem następujące hipotezy szczegółowe: 
 
1. Sdf-1 mobilizuje endogenne komórki macierzyste ze szpiku kostnego do regenerującego 
mięśnia szkieletowego, co może wspomagać regenerację mięśnia w przypadku 
niewystarczającej puli komórek satelitowych. 
 
2. Stymulacja komórek macierzystych za pomocą Sdf-1 powoduje zmiany w poziomie białek 
adhezyjnych zaangażowanych w migrację i fuzję komórek macierzystych. Zmiany w poziomie 
tych białek wpływają na wydajniejszą fuzję z komórkami mięśniowymi. 
 
3. Sdf-1, działając przez receptory Cxcr4 i Cxcr7, aktywuje wewnątrzkomórkowe ścieżki 
sygnalizacyjne regulujące aktywność i ekspresję białek zaangażowanych w migracje i fuzję. 
Stymulacja przeszczepianych komórek macierzystych za pomocą Sdf-1 zwiększa ich zdolność 
do uczestniczenia w regeneracji mięśnia.  
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Omówienie wyników opisanych w publikacjach włączonych do 
rozprawy doktorskiej. 
 
Mobilizacja endogennych komórek macierzystych ze szpiku kostnego do 
regenerującego mięśnia szkieletowego. Wykorzystanie cytokin Sdf-1 i G-CSF. 
 
Publikacja oryginalna 1: Sdf-1 and G-CSF treatment improves regeneration of Pax7-/- mice skeletal 
muscles:  
Kamil Kowalski, Rafał Archacki, Karolina Archacka, Władysława Stremińska, Anna Paciorek, 
Magdalena Gołąbek, Maria A. Ciemerych, Edyta Brzóska,  
JOURNAL OF CACHEXIA, SARCOPENIA AND MUSCLE, 2016; 7(4):483-96 
 
W warunkach fizjologicznych mięśnie szkieletowe ssaków regenerują bardzo dobrze. Komórki 
satelitowe, czyli komórki macierzyste mięśni szkieletowych, po uszkodzeniu mięśnia różnicują 
w mioblasty, które fuzjując ze sobą odtwarzają zniszczone włókna mięśniowe. W określonych 
sytuacjach regeneracja może być jednak utrudniona, bądź też zupełnie nie zachodzić.  
W przypadku człowieka przykładami takich sytuacji są urazy np. u chorych na nowotwór 
(kacheksja), bądź u osób w podeszłym wieku (sarkopenia). U takich osób pula komórek 
satelitowych jest mniejsza, a same komórki są mniej funkcjonalne. Badanie metod 
wspomagania regeneracji mięśni szkieletowych z wykorzystaniem myszy, jako modelu 
badawczego, jest trudne gdyż mięśnie tych zwierząt regenerują bardzo wydajnie. Istnieją 
jednak szczepy myszy transgenicznych, które umożliwiają częściowe odwzorowanie sytuacji, 
gdy regeneracja mięśnia nie zachodzi prawidłowo. Jednym z takich modeli badawczych  
są myszy pozbawione funkcjonalnych alleli genu Pax7. Myszy Pax7-/- cechuje złożony 
fenotyp. Jednak z punktu widzenia analiz regeneracji mięśni szkieletowych najistotniejsze jest 
to, że ich mięśnie cechuje prawie całkowity brak komórek satelitowych. Wykorzystując  
w moich badaniach ten model mogłem analizować regenerację mięśni szkieletowych 
zachodzącą przy istotnym niedoborze komórek satelitowych, a wiec komórek które  
w warunkach fizjologicznych odpowiedzialne są za naprawę tej tkanki. Byłem więc w stanie 
"zasymulować" sytuację, gdy uszkodzenie zachodzi w mięśniu, w którym komórki satelitowe 
nie są wystarczająco liczne lub nie są funkcjonalne. Mogłem więc sprawdzić, czy możliwa jest 
regeneracja mięśnia bez udziału mioblastów powstałych z komórek satelitowych, w oparciu  
o populację innych komórek macierzystych, np. tych endogennych, obecnych np. w szpiku 
kostnym. 
Największym wyzwaniem tego projektu była mobilizacja endogennych komórek 
macierzystych do regenerujących mięśni. Aby to osiągnąć wykorzystałem chemokinę Sdf-1, 
która kieruje migracją komórek powodując ich napływ zgodnie z jej rosnącym gradientem. 
Uszkodzony mięsień był nastrzykiwany roztworem Sdf-1, tak aby gradient tego czynnika był 
atraktantem dla komórek macierzystych obecnych w organizmie myszy Pax7-/-. Dodatkowo, 
w celu zwiększenia liczby komórek macierzystych, które mogą napłynąć do mięśnia 
szkieletowego, myszy były uprzednio stymulowane G-CSF (ang. Granulocyte - Colony 
Stimulating Factor), który powoduje uwolnienie komórek ze szpiku kostnego do krwioobiegu. 
W ten sposób powstał mysi model regeneracji mięśni szkieletowych zachodzącej bez udziału 
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komórek satelitowych, w oparciu o komórki macierzyste mobilizowane ze szpiku kostnego. 
Wstrzyknięcie Sdf-1 do regenerującego mięśnia powoduje, że napływa do niego większa liczba 
komórek syntetyzujących receptor Cxcr4 i marker CD34, a więc komórek macierzystych szpiku 
kostnego. Obecność tych komórek w mięśniu została zweryfikowana z wykorzystaniem analiz 
mRNA kodującego powyższe markery, jak i białka z zastosowaniem technik 
immunofluorescencyjnych, Western-blott oraz cytometrii przepływowej.  
Konsekwencją obecności w mięśniu komórek napływających w odpowiedzi na Sdf-1 był 
zarówno wzrost masy mięśnia jak i poprawa jego regeneracji, co przejawiało się mniejszym 
stopniem zwłóknienia, przy jednocześnie lepszej architekturze mięśnia. Mięśnie nastrzyknięte 
roztworem Sdf-1 w myszach stymulowanych G-CSF cechował również większy odsetek 
włókien eksprymujących zarodkową izoformę ciężkich łańcuchów miozyny. Ekspresja tej 
izoformy miozyny świadczy o obecności nowopowstałych włókien, czyli o prawidłowym 
procesie regeneracji. Zaobserwowałem również, że włóknom mięśniowym wyizolowanym  
z mięśni nastrzykniętych Sdf-1 towarzyszyło więcej komórek, w porównaniu do włókien  
z mięśni myszy kontrolnych.  
Zaprezentowane wyniki sugerują, że zastosowanie G-CSF i Sdf-1 może stanowić skuteczny 
sposób na wspomaganie regeneracji mięśni szkieletowych w przypadkach, gdy liczba komórek 
satelitowych nie jest wystarczająca. G-CSF powoduje mobilizację do krwioobiegu komórek 
potencjalnie mogących uczestniczyć w regeneracji, podczas gdy podany miejscowo Sdf-1 
tworzy gradient stymulujący napływ tych komórek do uszkodzonej tkanki.  
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Stromal derived factor-1 and granulocyte-colony
stimulating factor treatment improves regeneration of
Pax7/ mice skeletal muscles
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Abstract
Background The skeletal muscle has the ability to regenerate after injury. This process is mediated mainly by the muscle
specific stem cells, that is, satellite cells. In case of extensive damage or under pathological conditions, such as muscular dys-
trophy, the process of muscle reconstruction does not occur properly. The aim of our study was to test whether mobilized
stem cells, other than satellite cells, could participate in skeletal muscle reconstruction.
Methods Experiments were performed on wild-type mice and mice lacking the functional Pax7 gene, that is, characterized
by the very limited satellite cell population. Gastrocnemius mice muscles were injured by cardiotoxin injection, and then the
animals were treated by stromal derived factor-1 (Sdf-1) with or without granulocyte-colony stimulating factor (G-CSF) for
4 days. The muscles were subjected to thorough assessment of the tissue regeneration process using histological and
in vitro methods, as well as evaluation of myogenic factors’ expression at the transcript and protein levels.
Results Stromal derived factor-1 alone and Sdf-1 in combination with G-CSF significantly improved the regeneration of
Pax7/ skeletal muscles. The Sdf-1 and G-CSF treatment caused an increase in the number of mononucleated cells associ-
ated with muscle fibres. Further analysis showed that Sdf-1 and G-CSF treatment led to the rise in the number of CD34+ and
Cxcr4+ cells and expression of Cxcr7.
Conclusions Stromal derived factor-1 and G-CSF stimulated regeneration of the skeletal muscles deficient in satellite cells.
We suggest that mobilized CD34+, Cxcr4+, and Cxcr7+ cells can efficiently participate in the skeletal muscle reconstruction
and compensate for the lack of satellite cells.
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Introduction
Skeletal muscle fibres contain several hundred nuclei within a
continuous cytoplasm. Fibres are accompanied by muscle spe-
cific stem cells, that is, satellite cells that are localized between
the sarcolemma and the basal lamina. These cells are responsi-
ble for postnatal muscle growth and regeneration (reviewed in
Relaix and Zammit1). Responding tomuscle injury, satellite cells
become activated, become myoblasts, and fuse to form
myotubes and then new muscle fibres. Simultaneously, with
the activation of satellite cells, cytokines and chemokines
released locally upon injury attract inflammatory cells, which
infiltrate injured muscle and remove damaged fibres. Neutro-
phils are the first population of leukocytes that appear within
the injured muscle and participate in the removal of muscle
debris as well as exacerbate satellite cell activation. Then, mac-
rophages accumulate and phagocyte apoptotic and necrotic
cells and fibres, and they mediate the remodelling of the extra-
cellular matrix, the formation of new vessels, and activation of
myogenic precursors (reviewed in Rigamonti et al.2).
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The ability of satellite cells to reconstruct the damaged
muscle is remarkable. For example, it has been demonstrated
that satellite cells connected to a single muscle fibre can rec-
reate the number of myoblasts equal to the number of nuclei
forming the parent fibre within just 4 days following a muscle
injury.3 Moreover, satellite cells are capable of self-renewing
their population in adult muscles, which was first postulated
by Moss and Leblond.4 The capacity of satellite cells to self-
renew was experimentally proved by Collins and coworkers,
who transplanted a single muscle fibre together with few sat-
ellite cells to an injured skeletal muscle that was depleted of
endogenous satellite cells by irradiation.5 As a result of such
grafting, the functional muscle fibres were reconstructed,
and also a few hundred new satellite cells were observed.5
These results were confirmed by Sacco and coworkers, who
showed that even a single satellite cell transplantation
allowed the reconstruction of the injured muscle and the
restoration of the satellite cell pool.6 Importantly, these cells
were functional, that is, could orchestrate further rounds of
muscle regeneration. Therefore, satellite cells and myoblasts
resulting from them have been considered as myogenic cells,
which could be used in cell-based muscle therapy. The ability
of transplanted myoblasts to participate in muscle regenera-
tion and restoration of dystrophin expression was shown
using dystrophin deficient mdx mice.7 However, the results
of clinical trials using myoblasts for human Duchenne muscu-
lar dystrophy were disappointing (e.g. Karpati et al.8). Major
limitations in the application of satellite cells or myoblasts
in the management of muscular dystrophy is the restricted
ability of these cells to migrate through vasculature and
effectively engraft the injured muscle, as well as the rapid cell
death following transplantation, which could be overcome by
immunosuppression (reviewed in Briggs and Morgan9). On
the other hand, high-density injection protocols allow to
avoid the issue of limited migration of transplanted cells,
but are only applicable to easily accessible small muscle
groups.10 Apart from satellite cells, many other populations
of muscle-derived stem cells, bone marrow, or peripheral
blood cells manifest myogenic potential in vitro and in vivo.
The mesoangioblasts,11 pericytes,12 and CD133+ cells13 make
up the most interesting cells from the therapeutic point of
view. However, the majority of data on the use of various
stem cells in skeletal muscle therapy refers to the transplan-
tation of exogenous cells into the injured muscle. The func-
tions of endogenous cells, other than satellite cells, during
skeletal muscle regeneration remain largely obscure.
In the present study, we attempted to mobilize stem cells
into the site of the injury using stromal derived factor-1 (Sdf-1)
and to increase the number of mobilized stem cells using
granulocyte-colony stimulating factor (G-CSF). Bone marrow
is the main source of Sdf-1, but this cytokine is also expressed
in a wide variety of organs, such as the heart, liver, spleen, kid-
ney, and brain (reviewed in Cencioni et al.14). It is well
established that Sdf-1 induces migration of different stem cell
types, that is, satellite cells,15 CD34+ haematopoietic proge-
nitor cells,16 or mesenchymal stem cells.17 Sdf-1 mobilizes
transplanted stem cells to tissues affected by ischemia as it
was shown for limbs and hearts (e.g. Elmadbouh et al. and
Kuliszewski et al.18,19). G-CSF is the other factor involved in
the mobilization of stem cells from the bone marrow to peri-
pheral blood (reviewed in Alvarez et al.20). G-CSF was shown
to increase the level of cytokines in serum, reduce the num-
bers of bone marrow macrophages, inhibit the activity of oste-
oblasts, which are the main source of Sdf-1 in bone marrow,
increase the number of osteoclasts that release cathepsin K,
and activate the CD26 protease that degrades Sdf-1 (reviewed
in Hoggatt and Pelus21). Thus, the main mechanism of G-CSF
action relies on down-regulation of Sdf-1 level in the bone
marrow. G-CSF and erythropoietin induce neovascularization
of infracted rat myocardium, however, it is not clear whether
it involves the mobilization of endothelial progenitor cells
(EPCs). G-CSF also inhibits apoptosis of cardiomyocytes and
reduces the development of fibrosis in heart muscle.22
To study the impact of Sdf-1 and G-CSF on stem cell mobi-
lization to the injured muscle, we used mice lacking functional
Pax7 transcription factor (Pax7/). These mice are charac-
terized by a very limited satellite cell population23 and cannot
efficiently regenerate injured muscles.24 Thus, the induction of
skeletal muscle regeneration in Pax7/ mice must be de-
pendent on cells other than satellite cells. We aimed to verify
whether the endogenous (not transplanted) stem cells, mobi-
lized from bone marrow, could participate in muscle regenera-
tion and compensate for the lack of satellite cells.
Materials and methods
Mice
All performed experiments were approved by the Local Ethi-
cal Commission No 1 in Warsaw—permission No. 186/2011.
The 7-day-old male or female F1 (C57BI6N x 129Sv) Pax7+/+
(wt) and F1 (C57BI6N x 129Sv) Pax7/ mice were used.
C57BI6N Pax7+/ have been generated with the insertion of
a sequence encoding the neomycin gene into the first exon
of the paired box domain of one Pax7 locus according to the
method described previously.25 Such mutation leads to the
abolishment of DNA-binding activity of the Pax7 protein.
Next, C57BI6N Pax7+/ mice were crossed with 129Sv mice,
and F1 (C57BI6N x 129Sv) were generated.
Genotyping
Genomic DNA was isolated from the tails of 4- to 5-day-old
mice. Briefly, tail tips were cut and heated for 10min at 95°C
in 50mM NaOH. Then, 1M Tris (pH 8) was added, and sam-
ples were centrifuged, 1μL of supernatant was used for PCR.
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Reactions were performed with RedTaq Ready Mix (Sigma-
Aldrich, St. Louis, MO, USA) at the following conditions:
32 cycles of (30 s at 94°C, 30 s at 65°C, and 90 s at 72°C) pre-
ceded by 60 s at 94°C, and followed by 10min at 72°C. Geno-
types of Pax7/ mice were confirmed by PCR reaction
using the following primers:
[GGGCTTGCTGCCTCCGATATAGC,GTGGGGTCTTCATCAACGGTC,
TCGTGCTTTACGGTATCGCCGCTCCCG]. Wild-type allele was
represented by 200 kb product, while the Pax7- allele by
700 kb product.26
Muscle injury and treatments
Intact muscles: gastrocnemius muscles of 8-day-old F1
(C57BI6N x 129Sv) Pax7+/+ (wt) or Pax7/ male or female
mice were injected with 10ng/10μL (wt) or 5 ng/5μL
(Pax7/) of Sdf-1 (Life Technologies, Van Allen Way
Carlsbad, CA, USA) dissolved in 0.9% NaCl (saline). Contralat-
eral muscles were injected with the same volume of saline.
Next, 6 days after Sdf-1 treatment,wt and Pax7/mice were
sacrificed and the muscles were isolated. Injured muscles: both
gastrocnemius muscles of 7-day-old F1 (C57BI6N x 129Sv) Pax7
+/+ (wt) or Pax7/ male or female mice were injected with
5μL (wt) or 3μL (Pax7/) of cardiotoxin (ctx, 0.2mM,
Sigma-Aldrich). Twenty four hours post injury muscles were
injected with 10ng/10μL (wt) or 5 ng/5μL (Pax7/) of Sdf-
1. Contralateral muscles were injected with the same volume
of saline. Next, 4 or 7 days after injury, mice were sacrificed
and muscles were isolated. Additionally, 4 days after injury,
peripheral blood of the animals was collected. Sdf-1 and
G-CSF treatment: both gastrocnemius muscles of 7-day-old
F1 (C57BI6N x 129Sv) Pax7+/+ (wt) or Pax7/ male mice
were injected with 5μL (wt) or 3μL (Pax7/) of ctx. Starting
from the day of injury, animals were subcutaneously injected
with G-CSF (250ng per 1g of body weight).27 G-CSF was adminis-
trated twice a day, every 12h, for 4days. Twenty four hours post
injury muscles were injected with 10ng/10μL (wt) or 5ng/5μL
(Pax7/) of Sdf-1. Contralateral muscles were injected with
the same volume of saline. Next, 4 or 7 days after injury, mice
were sacrificed and muscles were isolated. Additionally,
peripheral blood mice was drawn from the animals at day 4
following injury. Figure 1A presents the experimental scheme.
Analysis of cell numbers associated with individual
fibres
Four days after injury, muscle fibres were isolated from wt
and Pax7/ mice gastrocnemius muscles, according to
the Rosenblatt method.28 Briefly, muscles were digested with
collagenase I for 1.5 h at 37°C. Next, single fibres were
transferred to single wells of 96-well plates coated with
10% Matrigel characterized by reduced growth factors
concentration (Becton Dickinson Bioscience, Franklin Lakes,
NJ, USA) and cultured in DMEM (Life Technologies) supple-
mented with 10% horse serum (HS, Life Technologies), 20%
fetal bovine serum (FBS, Life Technologies), 0.5% chicken
embryo extract (CEE, Sera Laboratories), and 1% antibiotic
(AB, Life Technologies). After 48 h of culture, the numbers
of cells that migrated off the individual fibres were counted.
After 72 h of culture, the morphology of the cells was
analyzed. Each culture was repeated five times.
Bone marrow-derived stem cells migration assay
Whole population of bone marrow cells was obtained fromwt
and Pax7/ mice. Bone marrow cells were washed in phos-
phate buffered saline (PBS) and centrifuged in Histopaque
1077 gradient (Sigma-Aldrich) to remove erythrocytes.
Obtained mononucleated cells were seeded on culture inserts
(8μm pore size) coated with Matrigel containing reduced
growth factor concentration (Becton Dickinson Bioscience)
and cultured in α-MEM (Sigma-Aldrich) supplemented with
2mM L-glutamine (Life Technologies), 20% FBS, and 1% anti-
biotic (penicillin and streptomycin, Life Technologies). After
48h of culture, non-adherent cells were removed. Next, culture
medium present in the lower chamber was supplemented with
Sdf-1 (50 ng/mL). After an additional 48h of culture, the cells
were fixed with methanol and stained with Giemsa (Merck,
Darmstadt, Germany), according to themanufacturer’s protocol.
The number of cells that migrated through the insert pores and
localized either at the insert surface facing the lower dish or at
the bottom of the lower chamber was counted. Analysis was
performed in triplicates.
Quantitation of mRNA levels
Total RNA was extracted from intact and injured muscles of
wt and Pax7/ mice using the RNasy Midi Kit (QIAGEN,
Venlo, Netherlands), according to the manufacturer instruc-
tion. 500 ng of total RNA was reverse transcribed using the
Transcriptor First Stand cDNA Synthesis Kit (Roche Applied
Science, Penzberg, Upper Bavaria, Germany), according to
the manufacturer’s protocol. mRNA levels were examined
using custom PCR array based on Universal ProbeLibrary
(Roche Applied Science) for the following genes: Cxcr4, Cxcr7,
Sdf-1, CD34, CD45, CD133,Myf5,m-cadherin, muscle creatine
kinase (m-CK), vascular endothelial growth factor (VEGF),
VEGF receptor (VEGFR), and embryonic myosin heavy chains
(eMyHC). Hypoxanthine phosphoribosyltransferase 1 (Hprt
1), glyceraldehydes-3-phosphate dehydrogenase (GAPDH),
and beta-2-microglobulin (B2m) were used as the candidate
reference genes. Quantitative real-time PCR analysis was per-
formed using the LightCycler 480 Probes Master 9.0 (Roche
Applied Sciences) and LightCycler 480 (Roche Applied
Sdf-1 and G-CSF improve regeneration 485
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 483–496
DOI: 10.1002/jcsm.12092
Figure 1 Regeneration of intact and injured wt and Pax7/ gastrocnemius muscles treated with stromal derived factor-1 (Sdf-1) or granulocyte-
colony stimulating factor (G-CSF) and Sdf-1. Analyses were performed at day 7 of regeneration. (A) Experimental design. (B) The level of Sdf-1 mRNA
normalized to the level of housekeeping genes. Data are the means ± SD. No statistically important differences were observed. (C) The muscle weight.
The statistically important differences are marked with stars. (D) The muscle cross sections stained with Masson’s trichrome. Bar 100 μm. (E) The level
of fibrosis showed as proportion of tissue area occupied by connective tissue. The statistically important differences are marked with stars. (F) The
level of fibronectin and tubulin protein. (G) The level of vascular endothelial growth factor (Vegf) and tubulin protein. (G’) The level of Vegf mRNA
normalized to the level of housekeeping genes. (H) The level of vascular endothelial growth factor receptor (VegfR) mRNA normalized to the level
of housekeeping genes. The statistically important differences are marked with stars.
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Sciences), according to the PCR array manufacturer protocol.
Threshold-cycle (Ct) values of the analyzed amplicons were
determined using the LightCycler 480 Software (Roche Ap-
plied Science). Expression levels were calculated with the
2-(ΔCT) formula using the relative quantification tool in the
LightCycler 480 Software. All the candidate reference genes
displayed high expression stability and were therefore used
for the normalization of the expression data. RNAs isolated
from three muscles of each group were analyzed.
Western blot analysis
The protein lysates frommuscles of 14-day-oldwt and Pax7/
mice were obtained using Complete Lysis-M EDTA-free re-
agent (Roche Applied Science) and denatured by boiling in
Laemmli buffer. Next, 25μg of protein samples were sepa-
rated using sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis and transferred to polyvinylidene difluoride
membrane (Roche Applied Science), according to previously
described protocol.15 Membranes were washed in Tris-
buffered saline (TBS), incubated in 5% non-fatty dry milk in
TBS at room temperature for 1 h, followed by the overnight
incubation in primary antibody diluted in 5% non-fatty dried
milk in TBST (1:2 000) at 4°C. Next, the membranes were ex-
posed for 2 h to HRP-conjugated secondary antibody diluted
in 5% non-fatty dry milk in TBST (1:10 000 or 1:20 000) at room
temperature. Protein bands were visualized using SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific)
and exposed to chemiluminescence positive film (Amersham
Hyperfilm ECL, GE Healthcare, Little Chalfont, UK). The expe-
riment was performed in triplicates, that is, three muscles of
each group were independently analyzed. The protein level
was quantified using the Gel Doc XR+ (BioRad, Hercules, CA,
USA) and Image Software System version 5.1 (BioRad). The
optical density of analyzed protein bands was compared with
tubulin bands. The following primary antibodies were used:
rabbit polyclonal anti-Cxcr4 (Abcam, Cambridge, UK), rat
monoclonal (MEC 14.7) anti-CD34 (Abcam), rabbit polyclonal
anti-Cxcr7 (Abcam), rabbit polyclonal anti-m-CK (Sigma-
Aldrich), mouse monoclonal (EP5) anti-fibronectin (Santa Cruz
Biotechnology, Dallas, TX, USA), and mouse monoclonal (B-5-
1-2) anti-tubulin (Sigma-Aldrich), rabbit polyclonal anti-VEGF
(Millipore, Billerica, MA, USA), and goat polyclonal anti-VEGFR
(Santa Cruz Biotechnology). The following secondary antibod-
ies were used: goat anti-mouse Igg (Sigma-Aldrich, dilution
1:20 000), goat anti-rabbit (Sigma-Aldrich, dilution 1:10 000),
and goat anti-rat (Calbiochem, dilution 1:10 000).
Histochemical staining
Six days after Sdf-1 injection to intact and injured gastrocne-
mius muscles of wt and Pax7/ mice, the muscles were
dissected. Next, muscles were frozen in isopentane cooled
with liquid nitrogen, transferred into 80°C, and cut into
7μm-thick sections using cryomicrotome (Microm HM505N).
Sections were hydrated in deionized water and fixed in
Bouin’s reagent (Sigma-Aldrich) overnight. Masson’s Trichrome
(Sigma-Aldrich) staining was performed according to the ma-
nufacturer protocol. Finally, sections were dehydrated and
mounted with Entellan (Merck). Sections were photographed
using Nikon Eclipse, TE200 microscope equipped with
Hoffman contrast. Fields of view (10 per each variant) were
analyzed using GIMP ImageJ to evaluate the percentage of
the tissue area occupied by connective tissue. Five muscles
collected during independent experiments were analyzed.
Immunolocalization
Gastrocnemius muscles of wt and Pax7/mice were frozen
in isopentane cooled with liquid nitrogen, transferred into
80°C, cut into 7μm-thick sections using cryomicrotome
(Microm HM505N). Muscle sections were hydrated in PBS
and fixed in 3% PFA for 10min. Next, samples were washed
with PBS, permeabilized with 0.05% TritonX100 (Sigma-
Aldrich) in PBS, incubated in 0.25% glycine (Sigma-Aldrich)
in PBS, followed by 1 h incubation in 3% BSA in PBS (Sigma-
Aldrich) containing 2% donkey serum (Sigma-Aldrich) at room
temperature. Next, all the samples were incubated at 4°C in
primary antibodies diluted in 3% bovine serum albumin
(BSA) in PBS (1:100), overnight. Subsequently, the specimen
were incubated for 2 h with secondary antibodies conjugated
with Alexa Fluor 488, 568, or 594 (Life Technologies) diluted
in 1.5% BSA/PBS (1:200), at room temperature. In order to
visualize the nuclei, samples were incubated for 5min at room
temperature with DraQ5 (Biostatus Limited, Leicestershire, GB)
diluted in PBS (1:1000). Finally, the samples weremounted with
Fluorescent Mounting Medium (DakoCytomation, Glostrup,
Denmark).
Single muscle fibres, isolated according to the Rosenblatt
method, were fixed for 10min with 3% PFA in PBS. Then
fibres were permeabilized in 0.5% TritonX100 (Sigma-Aldrich)
for 10min, incubated in 15mM NH4Cl for 20min, followed by
30min incubation with 10% HS (Life Technologies) at room
temperature. Next, fibres were incubated overnight at 4°C
with primary antibodies diluted in 10% HS in PBS (1:50),
which was followed by 1 h of incubation with secondary anti-
bodies conjugated with Alexa Fluor 488 or 594 (Life Techno-
logies) diluted in 10% HS/PBS (1:100), at room temperature.
Nuclei were visualized with DraQ5 (Biostatus Limited) diluted
in PBS (1:1000), incubated at room temperature, for 5min.
Fibres were mounted with Fluorescent Mounting Medium
(DakoCytomation).
The following primary antibodies were used: mouse
monoclonal anti-CD45 (Santa Cruz Biotechnology), rabbit
polyclonal anti-Cxcr4 (Abcam), rat monoclonal (MEC 14.7)
anti-CD34 (Abcam), rabbit polyclonal anti-Cxcr7 (Abcam), rabbit
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monoclonal (SP6) anti-Ki67 (Abcam), mouse monoclonal
(12G4) anti-m-cadherin (Abcam), mouse monoclonal (F1.652)
anti-eMyHC (Hybridoma Bank), and rabbit polyclonal anti-
laminin (Sigma-Aldrich). The following secondary antibodies
were used: donkey anti-mouse Igg Alexa 594 conjugated (Life
Technologies), donkey anti-rabbit Igg Alexa 488 conjugated
(Life Technologies), donkey anti-rabbit Igg Alexa 594 conju-
gated (Life Technologies), and goat anti-rat Igg Alexa 568 con-
jugated (Life Technologies). Appropriate controls of
secondary antibodies were performed. Each analysis was re-
peated three times.
Flow cytometry analysis
Four days after the injury of gastrocnemius muscles of wt and
Pax7/ mice, the peripheral blood (250μL) was collected
into the heparin containing tubes. The erythrocytes were
lysed using lysis buffer (0,17M Tris HCl, 0,16M NH4Cl,
pH 7.2). Simultaneously, gastrocnemius muscles were dis-
sected and incubated for 2 h at 37°C in 0.2% collagenase I
(Sigma-Aldrich), followed by 40min incubation in 0.05%
Dispase (Becton Dickinson Bioscience) at 37°C. Next, muscles
were fragmented by pipetting using 20G needle. Obtained
suspensions of cells and fibre fragments were filtered through
a 40μm cell strainer (Becton Dickinson Bioscience). Collected
cells were incubated for 30min with 0.5% BSA supplemented
with 1% FBS in PBS, at room temperature. Next, cells were
transferred to anti-CD34-PE (Abcam) or anti-Cxcr4 (Abcam)
primary antibodies diluted 1:100 in PBS with 0.5% BSA and in-
cubated for 30min at 4°C, washed in PBS, and then incubated
for 30min with secondary Alexa 488 conjugated antibody
diluted 1:200 (Life Technologies) at room temperature.
Finally, both blood and muscle-derived cells were fixed for
10min in 2% PFA in PBS, at room temperature. Samples were
analyzed using a FACSCalibur flow cytometer (Becton Dickinson
Bioscience). Control samples were incubated with isotype
fluorochrome matched immunoglobulin antibodies. Each
analysis was repeated five times.
Statistical analysis
Data was presented as means ± standard deviation. Student’s
t-test was used for statistical comparisons. P< 0.05 was con-
sidered significant and marked with an asterisk.
Results
Stromal derived factor-1 improves Pax7/
muscles regeneration
Our previous studies documented that Sdf-1 is produced dur-
ing skeletal muscles regeneration29, and exogenous Sdf-1 can
improve this process.15 Because this cytokine can increase
the mobilization of stem cells into injured muscle, we decided
to check whether it can also improve growth and regenera-
tion of skeletal muscles of Pax7/ mice, that is, mice lack-
ing satellite cells. Thus, by using Pax7/ mice, we analyzed
whether the endogenous stem cells would be mobilized by
Sdf-1 and would be able to substitute missing satellite cells.
We also mobilized stem cells from bone marrow to peripheral
blood using G-CSF. It allowed us to increase the number of
stem cells possibly able to engraft the injured muscles. To this
point, intact or ctx damaged gastrocnemius muscles of wt
and Pax7/ mice were injected either with saline (control)
or Sdf-1. Ctx injured muscles were also treated with G-CSF
(Figure 1A). To sumarize, the muscles of wt and Pax7/ mice
were analyzed in the following experimental variants: (1) intact
control and Sdf-1 injected (intact); (2) ctx injured control and
Sdf-1 injected (ctx); and (3) ctx injured and G-CSF treated
control and Sdf-1 injected (ctx + G-CSF) (Figure 1A). Three
and 6 days after Sdf-1 administration, that is, in either 11
or 14-day-old mice, we compared the progress and the
‘quality’ of growth as well as muscle regeneration.
The levels of Sdf-1 transcripts (endogenous Sdf-1) did not
differ between the muscles of 14-day-old mice, that is, at
day 7 of regeneration after ctx injection (Figure 1B). Impor-
tantly, the Pax7/ muscle mass and muscle fibres diameter
were smaller when compared with the wtmuscles. All wt and
Pax7/ muscles, that is, intact and regenerating that were
treated with Sdf-1, had a tendency to increase their mass
when compared with the control, that is, saline injected ones
(Figure 1C). Statistically significant differences (P< 0.05)
were observed only in the case of wt and Pax7/ mice that
were injured and treated with only Sdf-1 (Figure 1C). G-CSF
treatment did not have an effect on muscle mass. However,
treatment with Sdf-1 and G-CSF, alone or in combination,
significantly increased the ability of Pax7/ muscle to
reconstruct its structure, as shown in muscle cross sections
stained with Masson’s trichrome (Figure 1D). The regenera-
tion of untreated injured Pax7/ muscles (ctx and saline;
Figure 1D) was defective, clearly indicating regeneration
deficit at this stage (14-day-old mice, day 7 of regeneration
after ctx injection). At the same time, regeneration of injured
Pax7/ muscles treated with Sdf-1 proceeded more effi-
ciently (Figure 1D). Visualization of connective tissue in wt
and Pax7/ muscles with Masson’s trichrome showed lim-
ited fibrosis in Sdf-1 treated muscles (Figure 1D). Importantly,
the connective tissue area had a tendency to decrease in all
injured muscles injected with Sdf-1, regardless of mice geno-
type (Figure 1E). Statistically significant differences (P< 0.05)
in the fibrosis level were observed between injured Pax7/
muscles and treated with Sdf-1 muscles. In addition, the level
of fibronectin, which is characteristic for connective tissue,
was lower in Sdf-1 injected muscles (Figure 1F). In order
to verify whether Sdf-1 and G-CSF treatment enhances angio-
genesis, we assessed the angiogenic factor levels, that is, the
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transcript levels of Vegf and its receptor VegfR. The levels of
Vegf and VegfR did not differ significantly between saline and
Sdf-1 treated muscles of 14-day-old mice, that is, at day 7 of
regeneration (Figure 1G, 1G′, and 1H and Figure S1A in the
Supporting Information). Thus, it suggests that Sdf-1 did not
influence the blood vessel formation in regenerating muscles.
Importantly, G-CSF stimulation significantly increased the
level of Vegf and VegfR, implying that G-CSF stimulation im-
proves angiogenesis (Figure 1G, 1G′, 1H and Figure S1A).
Many lines of evidence showed that eMyHC is synthesized
in newly formed muscle fibres.30,31 For this reason, the aug-
mentation of eMyHC expression indicates an increase of
newly formed fibres number within the muscle. In intact wt
and Pax7/ muscles, the level of mRNA encoding eMyHC
was very low (Figure 2A). At the seventh day of regeneration,
ctx injury caused the increase in eMyHC transcript level in wt
and Pax7/ muscles (Figure 2A). Sdf-1 treatment insigni-
ficantly decreased eMyHC transcript levels in Pax7/
muscles. Interestingly, G-CSF stimulation resulted in dramatic
increase of eMyHC mRNA level in Sdf-1 treated Pax7/
(P< 0.05) but not wt muscles (Figure 2A). Immunolocaliza-
tion of eMyHC protein in regenerating wt and Pax7/
muscles confirmed results of qPCR analysis at the protein
level. The number of muscle fibres expressing eMyHC is pre-
sented in Figure 2B and C as their percentage in a total num-
ber of muscle fibres in the field of view (six muscles, 10 fields
of view per muscle). Analysis of ctx injured wt muscles re-
vealed low number of eMyHC positive fibres that decreased
as a consequence of Sdf-1 treatment. Pax7/muscles were
characterized by significantly higher number of eMyHC posi-
tive fibres, which also decreased following Sdf-1 treatment
(Figure 2B and C). Surprisingly, G-CSF and Sdf-1 injections
led to the dramatic increase in the formation of new, that
is, immature, muscle fibres in Pax7/ but not in wtmuscles
(Figure 2B and 2C). Moreover, the level of m-CK, which
expression is associated with muscle fibres maturation, was
Figure 2 Expression and localization of muscle specific factors in intact and injured wt and Pax7/ gastrocnemius muscles treated with stromal de-
rived factor-1 (Sdf-1) or granulocyte-colony stimulating factor (G-CSF) and Sdf-1. Analyses were performed at day 7 of regeneration. (A) The level of
embryonic myosin heavy chains (eMyHC) mRNA normalized to the level of housekeeping genes. Data are the means ± SD. The statistically important
differences marked with stars. (B) The proportion of muscle fibres number expressing eMyHC protein (eMyHC
+
fibres) of all muscle fibres at cross sec-
tion. The statistically important differences marked with stars. (C) Immunolocalization of eMyHC in newly formed muscle fibres. Green—laminin, red—
eMyHC, and blue—nuclei. Bar 50 μm. (D) The level of muscle creatine kinase (mCK) mRNA normalized to the level of housekeeping genes. Data are the
means ± SD. The statistically important differences marked with stars. (E) The level and analysis of mCK and tubulin protein.
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higher in ctx injured and Sdf-1 treated wt muscles compared
with untreated muscles (Figure 2D and 2E). Taken together,
this data indicates that Sdf-1 accelerates skeletal muscle
regeneration in wt and Pax7/ mice. G-CSF stimulation
followed by Sdf-1 treatment dramatically changed the
process of Pax7/ muscle regeneration and led to massive
formation of new immature muscle fibres (Figure 2B and 2C).
Importantly, maturation of these newly formed muscle fibres
was delayed in Pax7/ mice.
Granulocyte-colony stimulating factor and stromal
derived factor-1 treatment increases the
mobilization of the stem cells into injured muscles
Next, we attempted to identify endogenous stem cells that
would replace lacking satellite cells and improve skeletal
muscle regeneration in Pax7/ mice. Histological analysis
revealed that Sdf-1 injection resulted in the increase of mo-
nonucleated cells localized between muscle fibres (Figure 1D),
as compared with control ones (Figure 3A). G-CSF treatment
further increased the number of mononucleated cells that
engrafted ctx injured muscles, as compared with those
treated only with Sdf-1 (Figure 3A). Next, the expression of
mRNAs encoding stem cells markers, that is, CD34, Cxcr4,
and Cxcr7, was significantly increased in G-CSF and Sdf-1
injected regenerating muscles, as compared with saline
treated ones (Figure 3B). The level of mRNA encoding myo-
genic cells marker, that is, Myf5, was very low in Pax7/
as compared with wt muscles. In intact and ctx injured
muscles, neither Sdf-1 alone nor in combination with G-CSF
increased Myf5 expression, regardless of mice genotype
(Figure 3B). Analysis of mRNA encoding m-cadherin, another
satellite cells marker, revealed that its level was increased
only in Sdf-1-treated regenerating wt muscles (Figure 3B).
In Pax7/ muscles, m-cadherin expression did not change,
proving that their regeneration depends on cells other than
satellite cells or myoblasts derived from them (Figure 3B).
Histological analysis revealed that the number of CD34 and
Cxcr4 expressing cells and levels of these proteins in tissue
lysates were higher in both wt and Pax7/ muscles treated
with Sdf-1, as well as co-stimulated with G-CSF and Sdf-1 as
compared with untreated muscles (Figure 4A and 4B). The
effect of G-CSF and Sdf-1 treatment on Cxcr7 expression in
muscles was less pronounced (Figure 4B).
Figure 3 Analysis of mononucleated cells present in intact and injured wt and Pax7/ gastrocnemius muscles treated with stromal derived factor-1
(Sdf-1) or granulocyte-colony stimulating factor (G-CSF) and Sdf-1. Analyses were performed at day 7 of regeneration. (A) The number of mononucle-
ated cell counted on muscle cross sections stained with Masson’s trichrome. The statistically important differences marked with stars. (B) The level of
CD34, Cxcr4, Cxcr7, Myf5 and m-cadherin mRNA normalized to the level of housekeeping genes. The statistically important differences marked with
stars.
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To exclude the possibility that Sdf-1 increased the expres-
sion of Cxcr4 and CD34 in cells already present within the
muscle, we decided to isolate mononucleated cells from wt
and Pax7/ muscles at day 4 after injury and determine
the proportion of Cxcr4 or CD34 expressing cells by
fluorescence-activated cell sorting (FACS) analysis (Figure 4C
and 4D). In all samples obtained from either Sdf-1 or G-CSF
and Sdf-1 treated muscles, we observed the tendency that
the number of Cxcr4 and CD34 positive cells was higher,
as compared with non-treated muscles. To exclude the
Figure 4 Analysis of localization and level of CD34 and Cxcr4 in cells present in intact and injured wt and Pax7/ gastrocnemius muscles treated
with stromal derived factor-1 (Sdf-1) or granulocyte-colony stimulating factor (G-CSF) and Sdf-1. A. The presence of CD34 and Cxcr4 positive cells in
muscles at day 7 of regeneration. Green—Cxcr4, red—CD34, and blue—nuclei. Bar 20 μm. (B) The level of Cxcr4, CD34, Cxcr7, and tubulin protein
at day 7 of regeneration. (C) The proportion of Cxcr4 positive cells of all cells isolated from regenerating muscle measured by fluorescence-activated
cell sorting at day 4 of regeneration. (D) The proportion of CD34 positive cells of all cells isolated from regenerating muscle measured by FACS at day 4
of regeneration.
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possibility that Sdf-1 and G-CSF stimulate cell proliferation
but not their migration, we assessed the number of prolifer-
ating cells, that is, expressing Ki67, in regenerating muscles.
The number of Ki67 expressing cells was found to be compa-
rable in all the analyzed muscles at day 7 of regeneration
(Figure 5A). Thus, neither G-CSF nor Sdf-1 affected the prolif-
eration rate of resident cells but increased the number of
cells by promoting the homing of circulating cells into the
regenerating muscles. This result was confirmed by the anal-
ysis of muscle fibres that were isolated from wt and Pax7/
gastrocnemius muscles at day 7 of regeneration. Co-
localization of Ki67 and m-cadherin in the cells that were at-
tached to muscle fibres showed that the proportion of double
immunostained ones, that is, expressing both Ki67 and m-
cadherin, was comparable regardless of mice genotype and
type of muscle treatment (Figure 5B). Thus, we confirmed
that G-CSF and Sdf-1 did not affect the proliferation of resi-
dent cells, that is, satellite cells. In addition, we checked the
presence of so-called inflammatory cells within the analyzed
muscles. The level of mRNA encoding CD45, which is character-
istic for inflammatory cells, did not change in response to G-CSF
and Sdf-1 (Figure 5C), indicating that the cells present within
the muscle were not inflammatory ones. Additionally,
immunostaing for CD45 (Figure S1B) showed that CD45+ cells
were rarely observedwithin the analyzedmuscle. Thus, we sug-
gest that at day 7 of regeneration, infiltration of muscle tissue
by immune system cells is low. Moreover, the level of CD133
marker characteristic for circulating stem cells (AC133+) did
not differ between control and treated muscles (Figure 5D).
The source of the stem cells mobilized by stromal
derived factor-1 and granulocyte-colony
stimulating factor into injured muscles
To verify whether in our hands G-CSF promotes the release
of bone marrow stem cells (BMSCs) into circulation, we ana-
lyzed the peripheral blood for the presence of CD34 express-
ing cells. We did not detect any increase in CD34 positive cells
in the blood of wt and Pax7/ mice following muscle injury
with ctx, regardless of Sdf-1 treatment. However, G-CSF was
found to cause an increase in the number of CD34 expressing
cells in the peripheral blood of wt and Pax7/ mice, ana-
lyzed at day 4 of regeneration (Figure 5E). The number of
these cells was lower in those mice in which ctx-treated
muscles were Sdf-1 injected, suggesting their increased homing
to the site of injury. We also observed that G-CSF caused an in-
crease in the number of CD34 positive cells in blood of Pax7/
 mice which muscles were not injured (Figure 5E, grey bar).
Next, we compared ability of BMSCs of wt and Pax7/ mice
to migrate in Sdf-1 gradient. Transmembrane migration assay
showed that wt and Pax7/ BMSCs cells did not differ in
their migration potential (Figure 5F). Further analysis covered
the isolation of muscle fibres and cells from wt and Pax7 /
muscles at day 4 of regeneration. These fibres were cultured
individually for 48h, and cells that migrated out of them were
counted (Figure 5G and 5G′). The number of cells present in
the vicinity of the analyzed fibres was higher in fibres of mice
injected with G-CSF and Sdf-1, as compared with fibres isolated
from Sdf-1 or saline injected mice, regardless of their genotype.
Discussion
Our previous studies provided the evidence that Sdf-1 stimu-
lation improves skeletal muscle regeneration. This effect can
be linked to the presence of Cxcr4 and CD34 expressing
cells and also to the increase of myoblast migration capacity
in metalloproteinase-2 (MMP-2) and MMP-9-dependent
manner.15 Available data, however, do not provide straight-
forward proof showing that regeneration process can depend
on endogenous cells other than satellite cells. To verify such
notion, we studied mice carrying a targeted mutation in the
Pax7 gene (Pax7/). Pax7 has been shown to inhibit
satellite cells differentiation by inhibiting Myod1-dependent
activation of myogenin that is a crucial myogenic transcrip-
tion factor.32 Another myogenic transcription factor, that is,
Myf5, is also a direct target gene of Pax7.33 Previous study
showed that Pax7/ mice are significantly smaller than
wt and are characterized by a limited lifetime.34 We also
showed here that Pax7/ muscles, such as gastrocniemus,
had significantly lower mass comparing with wt ones. This
phenotype is caused by the reduced number of satellite cells
present in the skeletal muscles of Pax7/ mice. Satellite
cells from Pax7/ mice are characterized by cell cycle
arrest, inability to proliferate, and precocious differentia-
tion.23,24,35,36 Loss of satellite cells in Pax7/ mice is a
progressive process starting soon after the animal birth. In
10-day-old Pax7/ mice, satellite cell number drops to
15–25% of the number present in newborn mice.35,36 As a re-
sult, the satellite cells are hardly detectable. In adult Pax7/
mice, that is, 8weeks old.24 Pax7/mice are also charac-
terized by reduced muscle fibre size. This suggests defective
phase of postnatal skeletal muscle growth in these animals,
while it is known that this phase in wt mice is mediated by
satellite cells.23,35,36
As shown by Lepper and coworkers, the role of Pax7 could
be dependent on mouse age. Ablation of Pax7 expressing
cells during postnatal growth (between 7 and 18 days of
age) leads to the complete inhibition of regeneration. How-
ever, in adult mice (older than 21 days), Pax7 positive cells ap-
pear not to be essential for muscle regeneration, and their
ablation does not inhibit regeneration.37 On the other hand,
Rudnicki’s group showed that inactivation of Pax7 in satellite
cells of adult mice, that is, 40 days old, markedly impaired
muscle regeneration.38 Other authors report that in Pax7/
 mice older than 21 days, the regeneration process is re-
duced24,36 proving the substantial role of satellite cells in
skeletal muscle regeneration. This function of satellite cells
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Figure 5 Analysis of Ki67 positive cells (Ki67+) in intact and injured wt and Pax7/ gastrocnemius muscles treated with stromal derived factor-1 (Sdf-1)
or granulocyte-colony stimulating factor (G-CSF) and Sdf-1 (A and B). (E) Mobilization and migration ability of cells isolated at day 4 and 7 of
regeneration (C–G′). (A) The proportion of Ki67 positive nuclei (graph) of all nuclei at cross section and representative immunolocalization of Ki67
in wtmuscle at day 7 of regeneration. Red—nuclei, green—Ki76, and yellow—colocalization. Bar 50 μm. The statistically important differences marked
with stars. (B) The number of Ki67 and m-cadherin positive cells connected with freshly isolated muscle fibres (graph) and immunolocalization of Ki67
and m-cadherin at day 7 of regeneration. Bar 10 μm. The statistically important differences marked with stars. (C) The level of CD45 mRNA at day 7 of
regeneration, normalized to the level of housekeeping genes. The statistically important differences marked with stars. (D) The level of CD133 mRNA at
day 7 of regeneration, normalized to the level of housekeeping genes. The statistically important differences marked with stars. (E) The proportion of
CD34 positive cells (CD34
+
) in peripheral blood at day 4 measured by fluorescence-activated cell sorting. The statistically important differences marked
with stars. (F) The migration of wt and Pax7/ BMSCs in Sdf-1 gradient (transmembrane migration assay). The statistically important differences
marked with stars. (G) The number of cells associated with isolated at day 4 of regeneration muscle fibres after 48 h of in vitro culture. The statistically
important differences marked with stars. (G′) The presence of cells associated with muscle fibre after 48 h of in vitro culture. Transmitted light images.
Bar 100 μm.
Sdf-1 and G-CSF improve regeneration 493
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 483–496
DOI: 10.1002/jcsm.12092
was postulated from the very moment of their discovery.39
The essential role of satellite cells in adult muscle regenera-
tion was also demonstrated in other studies.40,41
Our work proves that defects in Pax7/ muscle regene-
ration can be ameliorated. By analyzing regenerating muscles
of 14-day-old Pax7/ mice, we showed that their regene-
ration is impaired and associated with the development of
fibrosis. However, by using G-CSF and then Sdf-1, we were
able to induce the mobilization of stem cells to the injured
muscles, ameliorated fibrosis and, in a consequence, made
the skeletal muscle regeneration effective, even in the
absence of satellite cells. The improvement of regeneration
was manifested in better muscle architecture, higher creatine
kinase levels, and lower fibrosis. Moreover, we observed
that G-CSF and Sdf-1 treatment led to the increase of VegfR
level that could suggest amelioration of angiogenesis. In-
deed, it was previously shown that combination of G-CSF
and Sdf-1 treatments enhanced neovascularization in ische-
mic muscles.42 This angiogenic effect can be another factor,
apart from mobilization of stem cells, improving reconstruc-
tion of regenerating muscles.
In growing Pax7/ skeletal muscles, the number of satel-
lite cells progressively decreases. Thus, in case of muscle
injury, improved muscular regeneration has to result from
stem cells mobilization. This hypothesis was proved by de-
tailed analyses of the cells present within regenerating mus-
cles of mice stimulated with G-CSF and Sdf-1. A very limited
number of previous studies documented that endogenous
(not transplanted) stem cells could, albeit with low frequency,
participate in the skeletal muscle reconstruction. First, it was
shown that muscle resident pericytes were able to contribute
to regeneration and also colonize the satellite cell niche.43
Next, it was demonstrated that endogenous bone marrow
cells with very low frequency can took part in the muscle
regeneration.44 Our results suggest that Pax7/ BMSCs
are able to react to Sdf-1 treatment and improve muscle re-
generation showing that they can participate in this process
regardless of functional Pax7. Furthermore, another study
suggested that BMSCs are able to undergo myogenic differ-
entiation in Pax7 independent manner.45
The main population of cells mobilized to injured wt and
Pax7/ skeletal muscles were CD34 and Cxcr4 positive
ones (but CD133 and CD45 negative). Importantly, as it was
shown by Ieronimakis and coworkers, the proportion of
CD34 expressing cells remains constant after mouse muscle
injury.46 Apart from the endothelial progenitors and stromal
cells, CD34 expression characterizes haematopoietic stem
and progenitor cells (reviewed in Lin et al.47). A low number
of CD34 positive cells is present in the peripheral blood and
could be significantly increased by a mobilization protocol
based on G-CSF administration (reviewed in Moggatt and
Pelus48). The reports concerning the influence of G-CSF on
myoblasts proliferation are conflicting. Some data document
that G-CSF does not influence myoblasts proliferation or
differentiation in vitro.49 Other lines of evidence imply that
G-CSF receptor is expressed in C2C12 myoblasts, and that
G-CSF strongly induces myoblasts proliferation in vitro.50
Moreover, the expression of G-CSF receptor was shown to
be elevated in regenerating muscle in mice, starting from
day 3 to 8 after ctx injury, that is, at the stages when myo-
blasts proliferate.50 Importantly, mice lacking functional
G-CSF receptor gene were characterized by diminished
regeneration, and G-CSF administration led to an increase
of the number of myoblasts and improved skeletal muscle
regeneration.50 Results of our experiments indicate, however,
that G-CSF used together with Sdf-1 does not affect the pro-
liferation of cells mobilized into the regenerating muscles of
Pax7/ mice at analyzed stage of regeneration. In wt mice,
such treatment increased the number of cells expressing Ki67
together with m-cadherin, suggesting that it stimulates only
satellite cells-derived myoblasts. We did not dissociate,
however, the action of G-CSF from Sdf-1.
As we have demonstrated, the administration of G-SCF and
Sdf-1 immediately after muscle injury can be very effective,
even in the case of skeletal muscles lacking satellite cells.
Fibrosis was diminished, and endogenous cells were mobi-
lized to the regenerating tissue. This observation can be
remove used during the development of the treatment of
many muscle diseases and impairments. However, as it
was shown previously, the frequency of the formation of
new fibres with the participation of transplanted bone
marrow stem cells is very low [e.g. Corbel et al.51], suggesting
that the major population of mobilized cells is not highly
effective in supporting skeletal muscle regeneration. This
can be a limiting factor for the therapies based on such cells.
In the current study, we showed that single administration of
Sdf-1 could be an effective stimulant increasing the participa-
tion of BMSCs in the skeletal muscle regeneration. Additional
increase in the number of stem cells present in the blood
stream, achieved by G-CSF injections, allows for the improve-
ment of the regeneration process. To conclude, the muscle
regeneration can be improved by treatment with Sdf-1 alone
or combined with G-CSF, even when the population of ske-
letal muscle specific stem cells, that is, satellite cells is nearly
exhausted. Our results add to the currently existing know-
ledge on the use of mouse model lacking satellite cells
for studying novel therapies of pathological conditions of
muscles with reduced satellite cell numbers.
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Fuzja komórek macierzystych z komórkami mięśniowymi w odpowiedzi na 
stymulację Sdf-1 
 
Publikacja oryginalna 2: Sdf-1 (CXCL12) induces CD9 expression in stem cells engaged in muscle 
regeneration 
Edyta Brzóska, Kamil Kowalski, Agnieszka Markowska-Zagrajek, Magdalena Kowalewska, Rafał 
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Wydajna regeneracja mięśni szkieletowych wymaga, aby komórki o potencjale miogenicznym 
były w stanie fuzjować ze sobą tworząc wielojądrowe miotuby, które dojrzewając odtwarzają 
uszkodzone włókna mięśniowe. Komórki mięśniowe wykazują zdolność do fuzji nie tylko  
in vivo, ale również w hodowli in vitro. Pozwala to w pewnym stopniu odwzorować pierwsze 
etapy różnicowania miogenicznego. Niezbędnymi czynnikami zaangażowanymi w fuzję 
komórek są białka adhezyjne. Badania prowadzone w Zakładzie Cytologii wskazywały na to, 
że mysie mioblasty stymulowane in vitro chemokiną Sdf-1 wykazują wyższy poziom białka 
adhezyjnego CD9. Również podanie Sdf-1 do regenerującego mięśnia szkieletowego myszy 
powoduje wzrost poziomu CD9.  
Wiedząc o wpływie Sdf-1 na poziom CD9 chciałem sprawdzić, czy niesie to ze sobą efekt 
biologiczny i może wspomagać regenerację. W tym celu wykorzystałem mysie komórki 
macierzyste: ESC oraz BMSC, które stymulowałem Sdf-1 i sprawdzałem in vitro, 
czy spowoduje to wzrost ich zdolności do fuzji. W tym celu komórki macierzyste umieściłem 
w hodowli mieszanej razem z mioblastami. W trakcie takiej hodowli komórki mięśniowe 
fuzjują tworząc wielojądrowe miotuby. Jeżeli dodane komórki takie jak ESC lub BMSC, mają 
zdolność do fuzji z mioblastami, to część miotub będzie hybrydowa, tj. utworzona z ich 
udziałem. Częstość, z jaką powstają takie hybrydowe miotuby odzwierciedla potencjał 
badanych komórek do uczestniczenia w regeneracji mięśni szkieletowych. 
Wykazałem, że BMSC stymulowane Sdf-1 zwiększały swoją zdolność do fuzji z mioblastami, 
co przekładało się na wyższy odsetek hybrydowych miotub. W przypadku ESC, które mają 
bardzo ograniczoną zdolność do fuzji z mioblastami, zaobserwowałem przede wszystkim 
zmianę w ich zdolności do migracji. ESC traktowane Sdf-1 zdecydowanie lepiej 
rozprzestrzeniały się w hodowli i zamiast tworzyć agregaty migrowały wzdłuż 
nowopowstających miotub. Wykorzystując technikę siRNA wyciszyłem w ESC ekspresję 
receptora Cxcr4. Dzięki temu wykazałem, że za wzrost poziomu CD9 po stymulacji  
Sdf-1 odpowiada aktywacja receptora Cxcr4. 
Roztwór białka Sdf-1 podawałem również do regenerującego mięśnia myszy pozbawionej 
funkcjonalnych alleli genu Pax7. Dzięki temu mogłem zweryfikować, czy brak komórek 
satelitowych w mięśniu zmienia jego odpowiedź na Sdf-1. Wykazałem, że w odpowiedzi  
na Sdf-1 następuje wzrost poziomu CD9 w mięśniach myszy Pax7-/- w sposób podobny jak  
w mięśniach myszy kontrolnych.  
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Izabela Plaskota1, Władysława Stremińska1, Katarzyna Jańczyk-Ilach1 and Maria A Ciemerych1Abstract
Introduction: Understanding the mechanism of stem cell mobilization into injured skeletal muscles is a prerequisite
step for the development of muscle disease therapies. Many of the currently studied stem cell types present myogenic
potential; however, when introduced either into the blood stream or directly into the tissue, they are not able to
efficiently engraft injured muscle. For this reason their use in therapy is still limited. Previously, we have shown
that stromal-derived factor-1 (Sdf-1) caused the mobilization of endogenous (not transplanted) stem cells into
injured skeletal muscle improving regeneration. Here, we demonstrate that the beneficial effect of Sdf-1 relies on
the upregulation of the tetraspanin CD9 expression in stem cells.
Methods: The expression pattern of adhesion proteins, including CD9, was analysed after Sdf-1 treatment during
regeneration of rat skeletal muscles and mouse Pax7-/- skeletal muscles, that are characterized by the decreased
number of satellite cells. Next, we examined the changes in CD9 level in satellite cells-derived myoblasts, bone
marrow-derived mesenchymal stem cells, and embryonic stem cells after Sdf-1 treatment or silencing expression
of CXCR4 and CXCR7. Finally, we examined the potential of stem cells to fuse with myoblasts after Sdf-1 treatment.
Results: In vivo analyses of Pax7-/- mice strongly suggest that Sdf-1-mediates increase in CD9 levels also in mobilized
stem cells. In the absence of CXCR4 receptor the effect of Sdf-1 on CD9 expression is blocked. Next, in vitro studies
show that Sdf-1 increases the level of CD9 not only in satellite cell-derived myoblasts but also in bone marrow derived
mesenchymal stem cells, as well as embryonic stem cells. Importantly, the Sdf-1 treated cells migrate and fuse with
myoblasts more effectively.
Conclusions: We suggest that Sdf-1 binding CXCR4 receptor improves skeletal muscle regeneration by upregulating
expression of CD9 and thus, impacting at stem cells mobilization to the injured muscles.Introduction
Skeletal muscle regeneration is a complex process of tis-
sue degeneration and reconstruction [1]. The process
mostly relies on the presence of muscle-specific uni-
potent stem cells; that is, satellite cells. However, the
myogenic potential has also been shown for other popu-
lations of stem and progenitor cells [2]. Quiescent satel-
lite cells that express transcription factor Pax7 are
located between myofiber sarcolemma and basal lamina.
In the response to muscle injury these cells are activated,
begin to proliferate, differentiate into myoblasts, and
fuse to form multinucleated myotubes and then muscle* Correspondence: edbrzoska@biol.uw.edu.pl
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unless otherwise stated.fibres. Satellite cell-derived myoblasts start to express
myogenic regulatory factors responsible for their proper
differentiation, such as Myod1, Myf5, Myf6, and myo-
genin [3]. The satellite cells, being muscle-specific stem
cells, appear to be the cells of first choice to be tested in
muscle therapies [4]. Nevertheless, for many reasons,
their use is still limited. Among the major obstacles pre-
venting the application of satellite cell-derived myoblasts
in therapy, one can include their restricted ability to mi-
grate through the vasculature to effectively engraft in-
jured muscle, their rapid cell death after transplantation,
and their limited regenerative capacity after in vitro cul-
ture [5].
Skeletal muscles serve as a niche not only for satellite
cells but also for a few other populations of stem cells.
These include muscle side population cells that were. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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33342 dye from their cytoplasm as well as the presence
of stem cell antigen Sca1 and CD45 proteins [6]. In 2002
Asakura and Rudnicki demonstrated that these cells
could fuse with myoblasts in vitro and also contribute to
the formation of 1% of new myofibres when transplanted
into the damaged anterior tibialis muscle of SCID mice
[7]. Next, a small population (0.25%) of muscle side
population-expressing satellite cell markers (that is, Pax7
and syndecan-4) as well as side population markers (that
is, ATP-binding cassette subfamily member ABCG2
transport protein and stem cell antigen Sca1) partici-
pated in the formation of 30% of muscle fibres when
transplanted into a damaged mouse anterior tibialis
muscle and as many as 70% of the myofibres when
transplanted into the anterior tibialis muscle of mdx
mice [8]. Other populations of stem cells present within
the skeletal muscle are pericytes associated with small
blood vessels [9], mesangioblasts [10-13], AC133 stem
cells that express CD133 [14], as well as PW1+/Pax7–
interstitial cells that synthesise PW1/PEG3 protein
involved in tumour necrosis factor alpha–nuclear factor-
κB signalling and do not express Pax7 protein [15].
These cells could undergo myogenic differentiation
in vitro and in vivo; that is, after transplantation into re-
generating mouse muscles. Furthermore, various tissues,
including skeletal muscle, house multipotential mesen-
chymal stem cells (MSCs) that are defined based on ad-
hesion to plastic, fibroblast-like morphology, intensive
proliferation in vitro, and the ability to differentiate into
adipocytes, chondrocytes, osteoblasts, and skeletal myo-
blasts [16,17]. MSCs isolated from mouse bone marrow
improved muscle regeneration and also reduced fibrosis;
that is, excessive development of connective tissue [18].
Moreover, MSCs isolated from the synovial membrane
participated in the regeneration of mouse skeletal mus-
cles and were present in the satellite cell niche. These
cells also partially improved the function of skeletal
muscle of mdx mice [17]. Additionally, many experi-
ments showed that the regeneration of skeletal muscle
can also be supported by stem cells isolated from tissues
other than skeletal muscle. Among these were stem cells
derived from bone marrow [19], human umbilical cord
blood [20,21], human umbilical cord Wharton’s jelly
[22], and hematopoietic stem cells [23]. Furthermore,
pluripotent stem cells such as embryonic stem cells
(ESCs) [24,25] or induced pluripotent stem cells [26-28]
could also follow a myogenic programme.
Even if many of the stem or progenitor cells manifest
myogenic potential, they are rarely readily available for
transplantation into injured muscle. First, transplant-
ation of exogenous stem cells can be only effective when
high doses of cells, ranging from 25 × 106/cm2 to 67.5 ×
106/cm2 cells, could be administered directly into themuscle (100 injections per 1 cm2) [29]. Second, trans-
planted cells are rarely able to migrate within injured
muscle and for this reason they usually remain only at
the site of the injection. Next, the method of cell admin-
istration can be also an issue. Despite their myogenic po-
tential, many of the stem cells tested were not able to
engraft injured muscle when transplanted into the
bloodstream. This makes their use in therapy rather dif-
ficult and limited. Presently, the major limitations that
contribute to the failure of clinical trials are caused by
the lack of specific methods supporting homing of the
stem cells after their systemic infusion. Summarising,
comprehensive in vitro and in vivo studies demonstrated
that many of stem cell populations are characterised by
myogenic potential; that is, the ability to differentiate
into myoblasts and muscle fibres and also to colonise
the satellite cell niche. Next, the transplantation of these
cells could improve regeneration of damaged muscles.
However, their physiological role in the reconstruction
of skeletal muscle remains unexplained.
In our previous study we showed that stromal-derived
factor-1 (Sdf-1, also known as CXCL12) treatment im-
proved skeletal muscle regeneration by enhancing en-
dogenous (not transplanted) stem cell mobilisation into
injured muscle [30]. Sdf-1 belongs to the cytokine family
and acts on the cells expressing receptor CXC chemo-
kine receptor (CXCR)-4 and/or CXCR7 [31]. Moreover,
we were also analysing the role of various adhesion pro-
teins in myoblast differentiation. M-cadherin [32], adhe-
sion protein complex composed of ADAM-12, CD9,
CD81, integrin beta1, and alpha3 [33], as well as
syndecan-4 were shown by us to be engaged in myoblast
differentiation [34]. Next, crucial function in this process
of such proteins as integrin alpha7 [35], alpha9 [36], and
other adhesion proteins was shown by other studies.
In the current study, we documented how Sdf-1 im-
pacts on myoblasts and other stem cell properties, im-
proving their ability to participate in the skeletal muscle
regeneration. We also show that preconditioning of stem
cells with Sdf-1 could be an effective approach to opti-
mise stem cell migration and engraftment to injured
muscles. Our results thus underline the mechanism that
could be activated in order to mobilise endogenous cells
into injured tissue. Importantly, this mechanism could
also be switched on in order to enhance homing of the
transplanted cells to the target tissues, and thus could
allow reduction of the number of cells needed for the
therapy.Materials and methods
All procedures involving animals were approved by
First Warsaw Local Ethics Committee for Animal
Experimentation.
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Rat satellite cell-derived myoblasts
Slow twitch soleus muscles were dissected from the hind
limbs of 3-month-old male WAG rats. The satellite cells
were isolated by muscle digestion with 0.15% pronase
(Sigma-Aldrich, St. Louis, MO, United States) in HAM’s F-
12 medium (Life Technologies, Carlsbad, California, United
States) buffered with 10 mM HEPES (Sigma-Aldrich) sup-
plemented with 10% foetal bovine serum (FBS; Life Tech-
nologies). Cells were plated on 2% gelatine-coated (Sigma-
Aldrich) dishes in complete Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies) supplemented with
10% FBS, 10% horse serum (Life Technologies), and 1% anti-
biotics (AB, 50 U/ml penicillin, 50 μg/ml streptomycin; Life
Technologies). Cells were cultured at 37°C in an atmosphere
of 5% carbon dioxide. The medium was changed every
2 days. Starting from day 3 of culture, cells were treated with
100 ng/ml Sdf-1. The control cells were cultured in the ab-
sence of Sdf-1 in the medium. The cells were subjected ei-
ther to quantitative RT-PCR, immunolocalisation, or western
blotting. The morphology of cells was analysed using a
Nikon Eclipse TE200 microscope (Nikon Instruments,
Tokyo, Japan) with Hoffman contrast.
C2C12 myoblasts
Mouse C2C12 myoblasts (obtained from the European Col-
lection of Cell Cultures, Porton Down, United Kingdom)
were plated in DMEM supplemented with 10% FBS and 1%
AB, on 2% gelatine-coated plates. Cells were cultured at 37°C
in an atmosphere of 5% carbon dioxide. The morphology of
cells was analysed using a Nikon Eclipse TE200 microscope
with Hoffman contrast. The cells were subjected either to
Sdf-1 treatment, transfection with small interfering RNA
(siRNA) complementary to mRNA encoding CXCR4, quan-
titative RT-PCR, or immunolocalisation or used for co-
culture experiments.
Mouse bone marrow-derived mesenchymal stem cells
The bones were dissected from the hind limbs of 3-month-
old male C57Bl6N mice carrying the lacZ transgene in the
ROSA26 locus. Next, the ends of the bones were cut and
bone marrow was washed out with saline using a 22 G nee-
dle. Obtained cells were washed twice with saline. Erythro-
cytes were then removed by gradient centrifugation in
Histopaque (Sigma-Aldrich) for 20 minutes at 1,800 rpm.
Obtained mononucleate cells were separated using a mag-
netic column (MACS; Miltenyl Biotec, Bergisch Gladbach,
Germany) with anti-CXCR4 specific antibody (Abcam, Cam-
bridge, United Kingdom), according to the manufacturer’s in-
struction. The CXCR4+ fraction of cells was cultured in α-
minimum essential medium (Sigma-Aldrich) supplemented
with 20% FBS, 200 mML-glutamine (Life Technologies), and
1% AB. The morphology of cells was analysed using a Nikon
Eclipse TE200 microscope with Hoffman contrast. Thecells were subjected either to Sdf-1 treatment, quantitative
RT-PCR, or immunolocalisation or used for co-culture
experiments.
Mouse embryonic stem cells
ESCs constitutively expressing histone H2B-GFP were pro-
vided by Dr Kat Hadjantonakis [37]. Mitomycin-inactivated
mouse embryonic fibroblasts, which served as the feeder
layer for ESCs, were plated on dishes coated with 1% gel-
atine (Sigma-Aldrich) in DMEM supplemented with 10%
FBS and 1% AB. Twenty-four hours later ESCs were seeded
onto the inactivated mouse embryonic fibroblasts and cul-
tured in knockout DMEM (Life Technologies) supple-
mented with 15% ES-qualified FBS (Life Technologies),
0.1 mM nonessential amino acids (Sigma-Aldrich),
200 mML-glutamine (Life Technologies), 0.1 mM β-
mercaptoethanol (Sigma-Aldrich), 1% AB, and 500 U/ml
leukaemia inhibitory factor (Chemicon, Billerica, MA,
United States). Prior to transfection, ESCs were separated
from mouse embryonic fibroblasts by the preplating tech-
nique and cultured on dishes coated with Matrigel Matrix
Growth Factor Reduced (1 mg/ml DMEM; BD Biosciences,
Becton-Dickinson, San Jose, CA, United States). The
morphology of cells was analysed using a Nikon Eclipse
TE200 microscope with Hoffman contrast. The cells were
subjected either to Sdf-1 treatment, transfection with
siRNA complementary to mRNA encoding CXCR4 or
CXCR7, quantitative RT-PCR, immunolocalisation, or west-
ern blotting or used for co-culture experiments.
Sdf-1 treatment and silencing of CXCR4 or CXCR7
expression by RNA interference
C2C12 or ESCs were plated on plates covered with
Matrigel Matrix Growth Factor Reduced (BD Biosci-
ences). After reaching 30 to 40% confluence the cells
were transfected with Silencer Select Pre-designed
siRNA (Life Technologies) complementary to mRNAs
encoding either CXCR4 9 (ID:s64091) or CXCR7
(ID:s64124). Appropriate, recommended negative con-
trol siRNA was used. siRNA duplexes were diluted in
DMEM to reach the concentration of 100 pmol per plate
and incubated with Lipofectamine RNAiMAX (Life
Technologies), according to the manufacturer’s instruc-
tions. After 24 hours the cells were treated with Sdf-1
(10 ng/μl). Next, cells were collected 48 hours post Sdf-1
treatment and processed either for mRNA isolation
followed by quantitative RT-PCR, immunolocalisation,
or western blotting. The efficiency of CXCR4 or CXCR7
downregulation was tested by quantitative RT-PCR and
immunocytochemistry.
Co-culture of stem cells and mouse C2C12 myoblasts
C2C12 myoblasts were plated at density of 3 × 104 in
DMEM with 10% FBS and 1% AB. When C2C12 cells
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derived mesenchymal stem cells (BM-MSCs) or ESCs –
control or pretreated with Sdf-1 – were seeded. Respect-
ively, 5 × 106 ESCs and 2 × 104 BM-MSCs were added.
After 24 hours the medium was changed for differentiation;
that is, DMEM supplemented with 3% horse serum and 1%
AB. After 14 days of co-culture, cells were fixed in 3% para-
formaldehyde (Sigma-Aldrich) and then processed for
immunolocalisation of selected antigens, as described
below. Skeletal myosin heavy and light chains (Sigma-Al-
drich) were localised to define differentiated myotubes in
ESC and myoblast co-cultures. β-galactosidase (Abcam)
was localised to identified BM-MSCs in co-cultures with
myoblasts. Cell nuclei were visualised with DraQ5 (Biosta-
tus Limited, Biostatus Ltd, Leicestershire, United Kingdom)
diluted in PBS. Cultures were analysed using confocal
microscope Axiovert 100 M (Zeiss, Carl Zeiss Inc., Jena,
Germany) and LSM 510 application software (Carl Zeiss
Inc., Jena, Germany). The same image acquisition settings
were used for all comparisons. For each experimental
group, the number of hybrid myotubes was counted from
50 random fields of view. Data are the mean ± standard de-
viation of three biological replicates. Results were analysed
by Student’s t test using GraphPadPrism (GraphPad Soft-
ware, Inc., La Jolla, CA, USA). Differences were considered
statistically significant when P <0.05.
Migration assay
BM-MSCs or ESCs were plated into the inserts of six-well
dishes (8 μm pores; BD Biosciences). Both inserts and wells
were coated with Matrigel Matrix Growth Factor Reduced.
After 24 hours of culture, the medium in the lower dish was
replaced with the medium supplemented with 50 ng/ml Sdf-
1. Control cells were cultured in medium lacking Sdf-1. After
48 hours of culture the cells were fixed and stained with
Giemsa (Merck, Merck KGaA, Darmstadt, Germany). The
number of cells that migrated from the inserts and localised
either at the membrane surface facing the lower dish or at
the bottom of the lower dish was counted. Three independ-
ent experiments were performed for each analysis. Data are
the mean ± standard deviation of three biological replicates.
Statistical analysis was performed with unpaired t test using
GraphPadPrism (GraphPad Software, Inc.). The results
were considered to be significantly different when P <0.05.
Muscle injury
The regeneration of slow twitch soleus skeletal muscles
was induced in 3-month-old male WAG rats. Briefly, the
animals were anaesthetised with pentobarbital sodium
salt (Sigma-Aldrich) by an intraperitoneal injection
(30 mg/kg body mass). Next, muscles were exposed, de-
nervated, and crushed as described previously [30]. Mus-
cles were injected with 100 ng Sdf-1 diluted in 20 μl
physiological saline. Two injections, 10 μl each, wereadministered into two different parts of muscle. The con-
trol muscles were injected with 20 μl physiological saline.
The animals were euthanised with carbon dioxide at days 1,
3, and 7 after the muscle injury. Next, injured muscles were
isolated, weighed, and collected for further analysis.
Quantitative RT-PCR
Total RNA was isolated from muscles, satellite cell-
derived myoblasts, and C2C12 myoblasts using the High
Pure Isolation Kit (Roche Applied Science, Penzberg,
Germany), according to the manufacturer’s protocol.
RNA was extracted from biological replicates (two C2C12
cultures or three primary cell cultures or three muscle
samples per each experimental time point). Then 100 ng
RNA from each sample was reverse-transcribed using the
RT2 First Strand Kit (SABiosciences, Qiagen, Valencia,
CA, United States) or the Transcriptor First Strand cDNA
Synthesis Kit (Roche Applied Science) according to the
manufacturer’s protocol, for muscles and myoblasts, re-
spectively. Next, mRNA levels in muscles and satellite
cell-derived myoblasts were examined using a custom
PCR array (SABiosciences) for the genes m-cadherin,
ADAM12, syndecan-4, CD9, CD81, integrin beta1 (itgb1),
alpha3 (itga3), alpha7 (itga7), and alpha9 (itga9) according
to the manufacturer’s protocol. mRNA levels in C2C12
myoblasts were examined using a custom PCR array based
on Universal ProbeLibrary (Roche Applied Science) for the
following genes: m-cadherin, ADAM12, CD9, CD81, itgb1,
itga3, itga7, and itga9. Hypoxanthine phosphoribosyltrans-
ferase 1 (Hprt1) [RefSeq:NM_012583], glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) [RefSeq:NM_017008],
beta-2-microglobulin (B2m) [RefSeq:NM_012512], and
acidic ribosomal phosphoprotein P1 (Rplp1) [RefSeq:NM_
001007604] were used as the candidate reference genes.
Quantitative real-time PCR analyses were performed with
the RT2 Real-Time PCR Master Mix (SABiosciences) in
the 7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, United States) or with the LightCycler
480 Probes Master 9.0 (Roche Applied Sciences) in the
LightCycler 480 (Roche Applied Sciences), according to
the PCR array manufacturer’s instruction. Threshold
cycle (Ct) values of the analysed amplicons were deter-
mined with SDS 2.1 software (Applied Biosystems) or
LightCycler® 480 Software (Roche Applied Science). Ex-
pression levels were calculated with the 2–(ΔCT) formula
using DataAssist™ software (Applied Biosystems) or the
relative quantification tool in LightCycler® 480 Soft-
ware. The geNorm™ algorithm integrated into DataAs-
sist™ was used to evaluate the stability of the candidate
reference genes. The expression level and standard de-
viation for each gene was represented as the column
charts using GraphPadPrism. All the candidate refer-
ence genes (B2m, Gapdh, Hprt, and Rplp1) displayed
high expression stability, as determined by the
Brzoska et al. Stem Cell Research & Therapy  (2015) 6:46 Page 5 of 15geNorm tool [38], and therefore were used for the nor-
malisation of the expression data. Data are the mean ±
standard deviation of two (C2C12) or three biological
replicates, each analysed in two technical replicates.
Results were analysed by ratio paired t test and differ-
ences were considered statistically significant when
P <0.05.
Analyses of mRNA levels in BM-MSCs and ESCs in-
cluded RNA isolation using the mirVana kit (Life Technolo-
gies) and then reverse transcription using Superscript (Life
Technologies). The TaqMan assays (Life Technologies) and
Master Mix (Life Technologies) were used to analyse the
level of the genes CXCR4, CXCR7, and CD9 according to
the PCR array manufacturer’s instructions. Hprt1 was used
as the reference gene. All reactions were performed in trip-
licates. The conditions of quantitative RT-PCR were as fol-
lows: reverse transcription, 25°C for 10 minutes, 42°C for
60 minutes, and 85°C for 5 minutes; quantitative PCR, tem-
plate denaturation, 95°C for 10 minutes, and 45 cycles of
95°C for 15 seconds and 60°C for 60 seconds. The collected
data were analysed using LightCycler 96SW 1.1 software
(Roche Applied Sciences). Data are the mean ± standard de-
viation of three biological replicates, each analysed in two
technical replicates. Results were analysed by paired t test
and differences were considered statistically significant
when P <0.05.
Immunocytochemistry
Selected antigens were immunolocalised in sections of re-
generating muscles, as well as in in vitro cultured cells.
Cells cultured were fixed with 3% paraformaldehyde for
10 minutes. Muscle cryosections were hydrated in PBS,
fixed in 3% paraformaldehyde and washed with PBS. Next,
sections or cells were permeabilised with 0.1% Triton
X-100/PBS (Sigma-Aldrich), and incubated with 0.25% gly-
cine (Sigma-Aldrich). Nonspecific binding of antibodies
was blocked with 3% bovine serum albumin (Sigma-Al-
drich) with 2% donkey serum (Sigma-Aldrich) for 1 hour.
Samples were then incubated with primary antibodies di-
luted 1:100 in 3% bovine serum albumin overnight,
washed with PBS, and incubated at room temperature
with secondary antibodies diluted 1:200 in 3% bovine
serum albumin for 1.5 hours. After washing with PBS,
cell nuclei were visualised by incubation with DraQ5
(Biostatus Limited) diluted 1:1,000 in PBS for 10 minutes.
Specimens were mounted with Fluorescent Mounting
Medium (Dako Cytomation, Glostrup, Denmark). After
the procedure was completed samples were analysed
using the confocal microscope Axiovert 100 M (Zeiss)
and LSM 510 software. The same image acquisition set-
tings were used for all comparisons. The following pri-
mary antibodies were used: rabbit polyclonal anti-skeletal
myosin (M7523; Sigma-Aldrich), rabbit polyclonal anti-
β-galactosidase (ab12081; Abcam), mouse monoclonalanti-integrin alpha3 (sc-7019; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit polyclonal anti-integrin beta1
(sc-9936; Santa Cruz), rabbit polyclonal anti-ADAM12
(ab39155; Abcam), rabbit polyclonal anti-CD9 (C9993;
Sigma-Aldrich), rabbit polyclonal anti-CXCR4 (ab2074;
Abcam), rabbit polyclonal anti-CXCR7 (ab117836; Abcam),
goat polyclonal anti-CD81 (sc-7102; Santa Cruz), mouse
monoclonal anti-M-cadherin (ab78090; Abcam), and rabbit
polyclonal anti-VCAM-1 (sc-8304; Santa Cruz). Secondary
antibodies directed against mouse or rabbit primary anti-
bodies conjugated with Alexa488, Alexa594, and Alexa633
were used (A21202, A11059, A21206, A11034, A11080,
A21203, A11037, A21071, A21082, A21063; Life Technolo-
gies). Appropriate controls of secondary antibodies were
performed.
Western blotting
Fifty micrograms of total protein lysate were denatured by
boiling in Laemmli buffer, separated using SDS-PAGE electro-
phoresis, and transferred to polyvinylidene fluoride mem-
branes (Roche Applied Science). The membranes were
washed, blocked with 5% Blotto (BioRad, Bio-Rad, Hercules,
CA, USA) and Tris-buffered saline for 1 hour, and incubated
at 4°C with primary antibodies diluted 1:2,000 in 5% Blotto
(BioRad) and Tris-buffered saline overnight, followed by sec-
ondary antibodies diluted 1:20,000 for 2 hours. Next, protein
bands were visualised with SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Fisher Scientific, Langenselbold,
Germany) and exposed to chemiluminescence positive film
(Amersham Hyperfilm ECL; GE Healthcare, Little Chalfont,
Buckinghamshire, United Kingdom). The obtained results
were analysed with GelDoc2000 using Quantity One software
(BioRad). Primary antibodies used were mouse monoclonal
anti-integrin alpha3 (sc-7019; Santa Cruz), rabbit polyclonal
anti-integrin beta1 (sc-9936; Santa Cruz), rabbit polyclonal
anti-ADAM12 (ab39155; Abcam), rabbit polyclonal anti-CD9
(C9993; Sigma-Aldrich), goat polyclonal anti-CD81 (sc-7102;
Santa Cruz), rabbit polyclonal anti-CXCR4 (ab2074; Abcam),
rabbit polyclonal anti-CXCR7 (ab117836; Abcam), rabbit poly-
clonal anti-M-cadherin (sc-10734; Santa Cruz), rabbit poly-
clonal anti-VCAM-1 (sc-8304; Santa Cruz), and mouse
monoclonal anti-tubulin (T5168; Sigma-Aldrich). Secondary
antibodies used were peroxidase-conjugate rabbit anti-mouse
(A9044; Sigma-Aldrich), peroxidase-conjugate rabbit anti-goat
(A5420; Sigma-Aldrich), and peroxidase-conjugate goat anti-
rabbit (A9169; Sigma-Aldrich). Three independent experi-
ments were performed.
Results
Sdf-1 treatment changes expression of adhesion proteins
during myoblast differentiation in vitro and in vivo in
regenerating muscle
In our previous studies we evidenced that Sdf-1 im-
proved muscle regeneration, stem cell mobilisation, and
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crucial role in the myogenic processes we decided to
focus on the possible link between Sdf-1 and those pro-
teins engaged in myoblast migration and differentiation.
To verify the existence of such a link we first focused on
skeletal muscle regeneration.
To follow the impact of Sdf-1 on regeneration, soleus
muscles of WAG rats were injected with Sdf-1 (100 ng
per muscle) after the muscle injury. Next, we analysed
nontreated (control) and Sdf-1-treated muscles at days 1
and 3 of regeneration (Figure 1). Activated satellite cells
start to proliferate (day 1), differentiate into myoblasts
(day 3) that fuse (day 7) to form myotubes, and recon-
struct damaged myofibres. The levels of mRNAs encod-
ing adhesion proteins (that is, i.e. m-cadherin, ADAM-
12, syndecan-4, CD9, CD81, integrin beta1, alpha3,
alpha7, and alpha9) were compared between control and
Sdf-1-treated muscles, at days 1 and 3 of regeneration.
At day 3, Sdf-1 significantly increased expression of m-
cadherin, ADAM-12, and integrin alpha9 at the mRNA
level (Figure 1A). Changes in mRNA levels was readily
translated to the levels of m-cadherin, ADAM-12, andFigure 1 Sdf-1 impact on the expression of adhesion proteins in rege
mRNAs encoding m-cadherin, ADAM-12, syndecan-4, CD9, CD81, integrin β
in control and Sdf-1-treated muscles (Sdf-1) at days 1 and 3 of regeneratio
control and Sdf-1-treated muscles at day 3 of regeneration. Bar = 50 μm. (C
day 7 of regeneration. (D) Level of m-cadherin, itga9, and CD9 protein dur
and 7 (C – intact muscle). *P <0.05. Error bars indicate standard deviation.integrin alpha9 proteins, which dramatically increased
in mononucleated cells present within the regenerat-
ing muscle (day 3), as shown by immunolocalisation
(Figure 1B). We did not observe significant changes in
the mRNAs encoding other analysed factors; that is,
syndecan-4, CD9, CD81, integrin beta1, alpha3, and
alpha7. However, immunolocalisation revealed that
Sdf-1 impacted one of the tetraspanins (that is, CD9).
Immunolocalisation of CD9 showed that this tetraspa-
nin was present in mononucleated cells both in con-
trol and Sdf-1-treated muscles at day 3 of regeneration
of the soleus muscle (Figure 1B). At day 7 of regener-
ation, CD9 was still detectable in mononucleated cells
and rarely in newly formed myofibres in control mus-
cles (Figure 1C). However, in Sdf-1-treated muscles
this protein was detectable in mononucleated cells
and significantly in the cell membranes of newly
formed myofibres (Figure 1C). Western blotting also
showed the changes at the protein level after Sdf-1
treatment (Figure 1D). The level of m-cadherin, itga9,
and CD9 increased at days 1 and 3 of muscle regener-
ation in response to Sdf-1 treatment. The changes innerating rat soleus muscle. (A) Quantitative RT-PCR analysis of
1 (itgb1), integrin α3 (itga3), integrin α7 (itga7), and integrin α9 (itga9)
n. (B) Immunolocalisation of m-cadherin, ADAM-12, itga9, and CD9 in
) Immunolocalisation of CD9 in control and Sdf-1-treated muscles at
ing control (ctrl) and Sdf-1-treated muscle regeneration at days 1, 3,
Figure 2 CD9 in control and injected with Sdf-1 skeletal muscles
of wild type and Pax7–/– mice. (A) Quantitative RT-PCR analysis of
mRNA encoding CD9 in wild type (wt) and Pax7–/– mice muscles at
day 7 of regeneration. (B) Immunolocalisation of CD9 in wt and Pax7–/–
mouse muscles at day 7 of regeneration. Nuclei, blue; adhesion pro-
teins, green. Bar = 30 μm. (C) Level of CD9 protein during control (C)
and Sdf-1-treated muscle regeneration of wt and Pax7–/– mice at day 7.
Error bars indicate standard deviation.
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Importantly, as we showed previously, Sdf-1 did not
change the number of rat satellite cell-derived myo-
blasts during in vitro culture, implying that it did not
impact the proliferation rate [30].
To determine whether Sdf-1 increases CD9 expression
in satellite cell-derived myoblasts or impacts on cells mi-
grating to the injured muscle, we decided to focus on
Pax7–/– mice. Previous analyses of this mouse model did
not show any abnormalities in embryonic myogenesis
[39]. However, postnatal development in Pax7–/– mice is
associated with a dramatic decrease in the population of
satellite cells, which causes the muscle growth retard-
ation [40]. As a result these mice are significantly
smaller than wild-type (wt) mice, have difficulty in mov-
ing, and usually die within 3 weeks of age. Analyses of
Pax7–/– muscles give us a unique opportunity to answer
the question about the identity of cells upregulating
CD9 within the injured muscle; that is, we were able to
test whether Sdf-1 treatment impacted on the resident
satellite cells (absent in Pax7–/– mice) or the cells that
were infiltrating injured muscle. Again, Sdf-1 treatment
increased the CD9 mRNA level only slightly (Figure 2A).
However, the level of CD9 protein was higher in Pax7–/–
and wt mice muscles as showed by immunocytochem-
istry and western blotting (Figure 2B,C). CD9 protein
exists in three forms with molecular masses between 22
and 27 kDa, and thus two CD9 bands were detected by
western blot. Summarising, we proved that Sdf-1
injected into the muscle upregulated the CD9 level also
in cells other than the satellite cells that either are
already present within or infiltrate regenerating muscle.
To answer the question of whether Sdf-1 also acts at sat-
ellite cells, we turn to the in vitro system.
The notion that Sdf-1 treatment results in upregula-
tion of CD9 in satellite cells was tested in in vitro experi-
ments in which we took advantage of primary rat
satellite cell-derived myoblasts. At day 5 of culture, sat-
ellite cell-derived myoblasts start to proliferate and then,
at day 7, fuse to form multinucleated myotubes. We did
not observe any significant differences in m-cadherin,
ADAM-12, syndecan-4, CD9, CD81, integrin beta1,
alpha3, alpha7, and alpha9 mRNA levels between control
and Sdf-1-treated cells at day 5 (nondifferentiated cells)
and day 7 of culture (fusing cells) (Figure 3A). When
Figure 3 Sdf-1 impacts on the expression of adhesion proteins (m-cadherin, ADAM-12, syndecan-4, CD9, CD81, integrin β1, integrin
α3, integrin α7, integrin α9) in differentiating rat satellite cell-derived myoblasts. (A) Level of mRNA at days 5 and 7 of control (C) and
Sdf-1-treated myoblast (Sdf-1) differentiation. (B) Immunolocalisation of adhesion proteins in control and Sdf-1-treated cells. Nuclei, blue; adhesion
proteins, green. Bar = 20 μm. (C) Level of adhesion proteins during control and Sdf-1-treated myoblast differentiation at day 7. itgb1, integrin β1;
itga3, integrin α3; itga7, integrin α7; itga9, integrin α9. *P <0.05. Error bars indicate standard deviation.
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tion and western blotting we observed a spectacular in-
crease only in the case of CD9 (Figure 3B,C).
Downregulation of Sdf-1 receptor (CXCR4) affects CD9
expression in C2C12 myoblasts
To further dissect the Sdf-1 impact on myoblast differ-
entiation we decided to manipulate the levels of its re-
ceptor; that is, CXCR4. In these experiments we used
mouse C2C12 myoblasts. The rationale behind the
choice of these cells is based on the fact that this cell
line not only serves as a standard in the studies on myo-
blast differentiation, but also is easy to manipulate and
transfect in in vitro culture. Expression of CXCR4 was
downregulated with specific siRNA. Forty-eight hours
following transfection with siRNA the level of CXCR4
mRNA decreased to 42.72 ± 2.39%, as compared with
cells transfected with control siRNA cells. In addition,
the level of CXCR7 mRNA, which was shown to be in-
volved in the Sdf-1 and interferon-inducible T-cell
chemoattractant signalling pathway [41], also slightlydecreased to 77.14 ± 8.39%. Downregulation of CXCR4
did not change significantly the levels of mRNAs encod-
ing adhesion proteins; that is, m-cadherin, ADAM-12,
syndecan-4, CD9, CD81, integrin beta1, alpha3, and
alpha7 (Figure 4A). Moreover, Sdf-1 treatment did not
impact on the levels of analysed mRNAs (Figure 4A).
However, the difference in ADAM12 mRNA level after
silencing CXCR4 expression and Sdf-1 treatment was
statistically significant (P = 0.046), but it was not statisti-
cally significant when compared with control. Next, the
expression of itga9 mRNA was very low and changed
neither after Sdf-1 treatment nor after downregulation of
CXCR4 (data not shown). The downregulation of CXCR4
level was translated to the protein level (Figure 4B). More-
over, the level of CD9 protein increased after Sdf-1 treat-
ment and decreased in response to CXCR4 downregulation
(Figure 4B). Immunolocalisation again proved that CXCR4
protein was not detectable in siRNA transfected cells
(Figure 4C). We also did not notice changes in the loca-
lisation and levels of m-cadherin, ADAM-12, syndecan-4,
CD81, integrin beta1, alpha3, alpha7, and alpha9
Figure 4 Level of CXCR4 and adhesion proteins in C2C12 myoblasts. (A) Quantitative RT-PCR analysis of mRNA encoding m-cadherin,
ADAM-12, syndecan-4, CD9, CD81, integrin β1 (itgb1), integrin α3 (itga3), integrin α7 (itga7), and integrin α9 (itga9) in control cells, treated with
Sdf-1, and transfected with CXCR4 siRNA (siRNA). (B) Western blotting analysis of CXCR4, CD9, and tubulin in control, Sdf-1-treated (Sdf-1) and
transfected with CXCR4 siRNA (siRNA) C2C12 myoblasts. (C) Immunolocalisation of CXCR4 and adhesion protein in control, treated with Sdf-1,
and transfected with CXCR4 siRNA (siRNA) C2C12 myoblasts. Nuclei, blue; adhesion proteins, green. Bar = 50 μm. CXCR, CXC chemokine receptor;
siRNA, small interfering RNA. *P <0.05. Error bars indicate standard deviation.
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induced CD9 upregulation (Figure 4C).Sdf-1 upregulates CD9 expression in bone marrow-derived
stem cells and embryonic stem cells
Our next question was whether Sdf-1 affected CD9 ex-
pression in stem cells other than satellite cells or cells
infiltrating the injured skeletal muscle. To address this
issue we decided to analyse two standard stem cell types
of different origin: multipotent adult BM-MSCs and
pluripotent ESCs. Both types of cells are extensively
studied as a source of cells that could be used in
therapy.Cells isolated from mouse bone marrow were sepa-
rated using a magnetic column and the fraction of
CXCR4-positive cells (BM-MSCsCXCR4+) – that is, only
the cells able to react to Sdf-1 – were analysed. We
showed that the level of CXCR4 protein is higher in
BM-MSCsCXCR4+ than in BM-MSCsCXCR4– or the whole
population of BM-MSCs (Figure 5A). Importantly, Sdf-1
treatment lead to the significant increase of CD9 mRNA
and protein levels in BM-MSCsCXCR4+ (Figure 5B,C).
CD9 protein exists in three forms with molecular masses
between 22 and 27 kDa, and thus two CD9 bands were
detected by western blot. Next, we tested the impact of
Sdf-1 on ESCs, control and transfected with siRNA
against CXCR4 or CXCR7. The mRNA and protein level
Figure 5 Sdf-1 impact on bone marrow mesenchymal stem
cells. (A) Western blotting analysis of CXCR4, CD9, and tubulin in
the whole population of bone marrow-derived mesenchymal stem
cells (BM-MSCs) as well as of CXCR4+ and CXCR4– BM-MSCs fractions
fractions. (B) Quantitative RT-PCR analysis of CXCR4 and CD9 mRNA in
BM-MSCs in control and Sdf-1-treated BM-MSCs. (C)Western blotting
analysis of CD9 and tubulin in control and Sdf-1-treated (Sdf-1) BM-MSCs.
(D) Migration of BM-MSCs in Sdf-1 gradient. The number of cells that
migrated from the inserts was counted. (E) Percent of hybrid myotubes formed
in co-culture of C2C12 myoblasts and control or Sdf-1 pretreated BM-MSCs. (F)
Co-culture of C2C12 myoblasts and control or Sdf-1 pretreated BM-MSCs
(green, localisation of β-galactosidase; blue, nuclei). Bar = 50 μm. CXCR,
CXC chemokine receptor. *P <0.05. Error bars indicate standard deviation.
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level of CXCR4 protein was significantly downregulated
in cells transfected with CXCR4 siRNA (Figure 6A,B).
Notably, in the response to Sdf-1, ESCs also upregulated
CD9 at the mRNA and protein levels (Figure 6A,B). Si-
lencing of CXCR4 lead to the downregulation of CD9
protein in ESCs (Figure 6B). Downregulation of CXCR4
did not change the protein level of the second Sdf-1 re-
ceptor; that is, CXCR7 (Figure 6B). We also decided to
silence expression of CXCR7 and observed that this only
slightly reduced the CD9 protein level (Figure 6B). How-
ever, silencing of CXCR7 expression was connected with
lower CXCR4 expression. We thus concluded that ob-
served lower CD9 protein expression could be the result
of CXCR4 downregulation.Stem cells treated with Sdf-1 migrate and fuse with
myoblast more effectively than control cells
Having found that Sdf-1, acting via CXCR4, upregulates
CD9 in myoblasts, cells infiltrating injured muscle, and
in such stem cells as BM-MSCs and ESCs, we decided
to assess whether this phenomenon contributes to the
improvement of skeletal muscle regeneration. We used
in vitro systems allowing assessment of the cell migra-
tion ratio and the myogenic potential of analysed cells.
First, the migration of BM-MSCs and ESCs in re-
sponse to Sdf-1 was analysed. Using the transwell migra-
tion system we showed that the number of BM-MSCs
which migrated in response to Sdf-1 increased 3.0 times
(Figure 5D). The number of ESCs that migrated in-
creased 3.25 times in the presence of Sdf-1 (Figure 6C).
Silencing of CXCR4, but not CXCR7, expression lead to
the decrease of ESC migration in response to Sdf-1
treatment (Figure 6C). Next, we analysed how Sdf-1 im-
pacts on the myogenic potential of BM-MSCs or ESCs.
To this point, we co-cultured cells pretreated with Sdf-1
with differentiating C2C12 myoblasts. Analysis of co-
culture of BM-MSCs with C2C12 cells revealed that they
were able to form 2.93 ± 2.3% of hybrid myotubes; that
is, tubules formed as a result of fusion between tested
stem cells and C2C12 myoblasts. Sdf-1 pretreatment in-
creased this number to 9.63 ± 3.5% (Figure 5E,F). Control
ESCs were able to form 0.41 ± 0.38% of hybrid myotubes.
In response to Sdf-1 pretreatment, the number of hybrid
myotubes increased to 1.13 ± 0.64% (Figure 6D,E). As
we have shown previously, ESCs very rarely fuse with
myoblasts [42]. The observed increase in the fusion
index after Sdf-1 treatment was thus an interesting re-
sult. Taken together, our results indicate that Sdf-1 up-
regulated CD9 expression in a CXCR4-dependent, but
not a CXCR7-dependent, manner, induced stem cell
migration, and increased myogenic potential of ana-
lysed stem cells.
Figure 6 Sdf-1 impact on embryonic stem cells. (A) Quantitative RT-PCR analysis of CXCR4 and CD9 mRNA in control and Sdf-1-treated
embryonic stem cells (ESCs). (B) Western blotting analysis of CXCR4, CXCR7, CD9, and tubulin in control, Sdf-1-treated (Sdf-1), and either CXCR4
(siRNA CXCR4) or CXCR7 siRNA-treated (siRNA CXCR7) ESCs. (C) Migration of control or transfected with CXCR4 or CXCR7 siRNA ESCs in response
to Sdf-1 gradient. (D) Proportion of hybrid myotubes formed in co-culture of C2C12 myoblasts and control or Sdf-1 pretreated ESCs. (E) Co-culture of
C2C12 myoblasts (red) and control or Sdf-1 pretreated ESCs (green); nuclei, blue. Bar = 50 μm. CXCR, CXC chemokine receptor. *P <0.05. Error bars
indicate standard deviation.
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Previously, we showed that Sdf-1 improved regeneration
of injured skeletal muscles by inducing stem cell mobil-
isation to injured muscle and also increasing myoblast
migration via matrix metalloproteinases MMP2 and
MMP9 [30]. However, Sdf-1 did not change the expres-
sion of myogenic regulatory factors either in vivo or
in vitro [30]. Next, many lines of evidence, including our
own studies, showed that adhesion proteins play a cru-
cial and indispensable role in skeletal muscle regener-
ation [32,33,43,44]. Thus, in the current work we tested
whether and how Sdf-1 affects expression of adhesion
proteins engaged in myoblast migration and differenti-
ation. We found that the levels of adhesion proteins in-
creased in Sdf-1-treated muscles but not in in vitro
cultured myoblasts (primary culture or cell line). This
led us to the suggestion that in vivo the increase of m-
cadherin, integrin alpha9, and ADAM12 could occur in
cells other than myoblasts engaged in the regeneration
of skeletal muscle. Nevertheless, our most important ob-
servation was that Sdf-1 induced upregulation of CD9
in vivo during wt and Pax7–/– muscle regeneration andin in vitro cultured myoblasts and such stem cells as
BMSCs and ESCs.
CD9 is a 21 to 24 kDa surface molecule that belongs
to the tetraspanins, a family of four-transmembrane do-
main proteins associated with integrin receptors, which
was described as motility-related factor engaged in mi-
gration of multiple cancer cell lines [45]. CD9 was also
shown to be associated with such integrins as α3β1,
α4β1, α5β1, α6β1, α6β4, and αIIbβ3 [45]. Interactions of
CD9 with integrins led to changes in their conformation
and activation, which results in the modulation of
integrin-dependent signalling pathways [46]. Moreover,
CD9 is directly associated with EWI-2 and CD9P-1 (also
known as EWI-F or FPRP, member of the immuno-
globulin superfamily), epidermal growth factor receptor,
and discodin domain receptor DDR1 [47-49]. Addition-
ally, the tetraspanin network modulates membrane-type
1 matrix metalloproteinase cell surface localisation and
is able to induce expression and also activate MMP2
[50,51]. By impacting at matrix metalloproteinases, CD9
may regulate not only cell migration but also tissue re-
modelling during embryonic development, angiogenesis,
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ation. Importantly, CD9 was also shown to play a role in
muscle fibre formation [52]. In 1999 Tachibana and
Hemler documented that anti-CD9 antibodies inhibited
fusion of mouse C2C12 myoblasts, without affecting
muscle-specific protein expression such as myosin heavy
chains, desmin, and actin [52]. In our previous study, we
also showed that the complex of CD9 and integrin α3β1
plays a pivotal role during satellite cell-derived myoblast
fusion and skeletal muscle regeneration [33]. Interest-
ingly, β1-deficient myoblasts that were unable to fuse
did not express CD9 [53]. Moreover, Charrin and co-
workers showed that proper muscle regeneration re-
quired CD9 and CD81 function [54]. They demonstrated
that mice lacking either CD9 or CD81, or both CD9 and
CD81, were unable to properly regenerate their skeletal
muscles. During reconstruction of CD9 and CD81-
deficient muscle, myoblasts formed giant dystrophic
myofibres. Also in vitro absence of both CD9 and CD81
led to hyperfusion of myoblasts. Myoblasts lacking either
CD9 or CD81 fused in vitro normally.
If a lack of CD9 decreases cell fusion, then its upregu-
lation should have the opposite effect. Indeed, human
rhabdomyosarcoma-derived myoblasts overexpressing
CD9 formed approximately fourfold more syncytia than
control cells [52]. In the current study we showed that
Sdf-1 seems to be a perfect trigger leading to the in-
crease in the CD9 proteins levels that promotes skeletal
muscle regeneration via induction of stem cell migration
and fusion with myoblasts. First, we noticed that Sdf-1
treatment results in upregulation of CD9 in myoblasts in
a CXCR4-dependent way. Next, using Pax7–/– mice, we
showed that Sdf-1 treatment also increased CD9 expres-
sion in cells other than satellite cells and differentiatingFigure 7 Myogenic potential of stem cells is not sufficient to apply the
in a Sdf-1 CXCR4-dependent way leads to increased ability of stem cell linesmyoblasts; that is, stem cells that infiltrate regenerating
muscles. Our in vitro studies focusing on BM-MSCs and
ESCs proved that stem cells are prone to Sdf-1/CXCR4-
dependent CD9 induction, which leads to their increased
migration and ability to fuse with myoblasts. Thus, we
suggest that preconditioning of stem cells with Sdf-1
could be an alternative approach to optimise stem cell
migration and engraftment after their injection into in-
jured skeletal muscle. Presently, the major limitation
causing the failure of clinical trials is the lack of specific
homing of cells transplanted into injured tissue [55].
Some evidence shows that Sdf-1 treatment could be a
strategy to improve the therapeutic potential of stem
cells [56]. Sdf-1 treatment of endothelial progenitor cells
improved their migration and adhesion to activated
endothelium [57]. Sdf-1-treated endothelial progenitor
cells from human umbilical cord or cord blood upregu-
lated expression of integrins (α4 and αM) and MMP2 se-
cretion [57]. Moreover, Sdf-1-treated mesangioblasts
migrated more effectively in vitro, and in vivo efficiently
engrafted mouse dystrophic muscles improving the re-
construction of muscle fibres [58]. BM-MSCs precondi-
tioning with Sdf-1 increased cell viability, proliferation,
and vascular endothelial growth factor secretion in vitro
[59]. Sdf-1 was also shown to promote homing and
proliferation of transplanted MSCs into infarcted myo-
cardium [59]. Importantly, rat hearts transplanted with
Sdf-1-pretreated MSCs showed significant neoangionesis
in the ischaemic area [59].
The therapeutic potential of MSCs such as BM-MSCs
is extensively explored. MSCs can be easily isolated from
adult tissues and cultured in vitro. Notably, these cells
exhibit no significant immunogenicity [60,61] and are
able to differentiate into various cell types, producingm in damaged skeletal muscle therapy. Induction of CD9 expression
to migrate and fuse with myoblasts. CXCR, CXC chemokine receptor.
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apoptotic, anti-inflammatory, and pro-angiogenic prop-
erties [62]. MSCs are also able to effectively follow the
myogenic programme [17]. On the other hand, ESCs
that are characterised by the potential to differentiate
in vivo into any given cell type fail to efficiently produce
some cell types in vitro. Myogenic differentiation of
ESCs does not occur spontaneously even in embryonic
bodies that mimic spatiotemporally early embryonic de-
velopment [63,64]. As was shown by Darabi and co-
workers, ESC overexpression of Pax3 or Pax7 can
effectively drive the cells into a myogenic programme
[25,26,65]. Other in vitro methods, such as culture con-
ditions [66] or various chemical treatments [67], are far
less effective. Here, we showed that upregulation of
CD9, as the result of Sdf-1 pretreatment, leads to the in-
crease in ability to migrate and fuse with myoblasts of
these two stem cell lines; that is, BM-MSCs and ESCs.
The mechanism of CD9 expression is particularly in-
teresting. It is known that CD9 mRNA exists in two
major RNA species differing only in the length of their
5′ untranslated region [68]. Efficient mRNA translation
depends, among other factors, on the supportive RNA
folding of the 5′ untranslated region; that is, the region
which contains the initiation codons. The long and short
forms of the 5′ untranslated region of CD9 mRNA have
different stability. The long 5′ untranslated region is
characterised by a complex secondary structure com-
prising a stable stem-loop. A shift from shorter to longer
5′ untranslated regions influences the CD9 protein level.
Thus, not only a reduction or increase in the absolute
quantity of CD9 mRNA can reduce or increase the level
of CD9 protein. Moreover, the mechanism of CD9 up-
regulation is concerned with some suggestions coming
from the study, which showed in human CD34+ cells
isolated from cord blood that Sdf-1 acting through
CXCR4 induced expression of CD9 via G-proteins and
kinases they activate – protein kinase C, phospholipase
C, extracellular signal-regulated kinase, and Janus kinase
2 signals [69]. Furthermore, pretreatment of human
CD34+ cells with anti-CD9 antibody significantly im-
paired their spleen and bone marrow homing [69].Conclusions
The myogenic potential of stem cells is not sufficient to
apply the cells in damaged skeletal muscle therapy. Here,
we have shown that Sdf-1, through the CXCR4 receptor,
induced expression of tetraspanin CD9 in satellite cell-
derived myoblasts, ESCs, and BM-MSCs. We showed
that upregulation of CD9 led to an increase in the ability
of stem cells lines to migrate and fuse with myoblasts
(Figure 7). Induction of CD9 could thus increase the
therapeutic potential of stem cells.Abbreviations
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Analiza wewnątrzkomórkowych ścieżek sygnalizacyjnych zaangażowanych w 
migrację komórek w odpowiedzi na Sdf-1. Wpływ Sdf-1 na zdolność 
przeszczepianych komórek macierzystych do uczestniczenia w regeneracji 
mięśnia. 
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Sdf-1 jest chemokiną oddziałującą z dwoma receptorami Cxcr4 oraz Cxcr7. Zdecydowana 
większość badań dotycząca Sdf-1 opisuje efekty stymulacji receptora Cxcr4, który odpowiada 
głównie za migrację komórek. Znacznie mniej wiadomo o funkcji receptora Cxcr7. Część  
z opublikowanych badań świadczy o tym, że pełni jedynie funkcję "gąbki" dla Sdf-1,  
przez co zmniejsza pobudzenie Cxcr4. Wyniki innych badań pokazują, że jest to funkcjonalny 
receptor.  
W trakcie prowadzonych doświadczeń chciałem sprawdzić, który z receptorów Cxcr4 czy 
Cxcr7 jest zaangażowany w odpowiedź komórki na Sdf-1. Dodatkowo postanowiłem 
zidentyfikować wewnątrzkomórkowe ścieżki sygnalizacyjne aktywowane w odpowiedzi na 
Sdf-1. W tym celu analizowałem hodowane in vitro ESC, MSC i mioblasty pierwotne uzyskane 
z komórek satelitowych izolowanych z mięśni szkieletowych. Komórki te transfekowałem 
odpowiednio zaprojektowanymi siRNA, co pozwalało mi obniżyć poziom ekspresji Cxcr4 bądź 
Cxcr7. Następnie komórki traktowałem Sdf-1. Dzięki temu mogłem odróżnić, który receptor 
jest odpowiedzialny za obserwowaną odpowiedź. Wykazałem, że badane komórki migrują  
w gradiencie Sdf-1 w sposób zależny wyłącznie od receptora Cxcr4. Sdf-1 nie wpływa na 
proliferację komórek niezależnie od tego, który receptor był aktywowany. Stymulacja Sdf-1 
powoduje wzrost aktywności GTPaz: Rac-1 oraz Cdc42, a więc czynników odpowiedzialnych 
za rearanżację cytoszkieletu aktynowego uczestniczącego w migracji komórek. Efekt ten 
zostaje zniesiony po wyciszeniu ekspresji receptora Cxcr4, podczas gdy obniżenie poziomu 
Cxcr7 nie wpływa na wymienione GTPazy. Wykazałem również, że stymulacja badanych 
komórek powoduje wzrost poziomu ufosforylowanej (aktywnej) formy FAK  
(ang. Focal Adhesion Kinase). FAK w ufosforylowanej formie jest odpowiedzialna za 
tworzenie płytek przylegania, które z kolei są elementem niezbędnym w trakcie migracji 
komórek. Wyciszenie ekspresji receptora Cxcr4 podobnie jak Cxcr7 powoduje wyraźne 
obniżenie poziomu ufosforylowanej formy tej kinazy. Wykorzystując technikę mikromacierzy 
analizowałem również transkryptom ESC stymulowanych Sdf-1, także takich w których 
wyciszyłem ekspresję Cxcr4 lub Cxcr7. Wyciszenie ekspresji Cxcr4 wpływało na spadek 
poziomu transkryptów genów zaangażowanych w m.in. na migrację i adhezję. W przypadku 
wyciszenia ekspresji Cxcr7 spadkowi ulegała przede wszystkim ekspresja genów związanych 
z białkami cytoszkieletowymi (np. aktyna). 
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Opisane doświadczenia pozwoliły mi na wykazanie, że Sdf-1 promuje migrację komórek  
w sposób zależny od receptora Cxcr4 i niezależny od receptora Cxcr7. Aktywacja migracji 
zachodzi za pośrednictwem GTPaz Cdc42 i Rac1. Wiedząc to, zaplanowałem kolejny etap 
doświadczeń, w którym komórki stymulowane Sdf-1 i/lub takie, w których wyciszyłem 
ekspresję receptora Cxcr4 lub Cxcr7, przeszczepiałem do regenerującego mięśnia 
szkieletowego, Pozwoliło mi to przetestować ich zdolność do uczestniczenia w tworzeniu 
włókien mięśniowych. Dodatkowo stymulowałem sam mięsień wstrzykując do niego roztwór 
Sdf-1. Zakładałem, że jeżeli uda mi się zwiększyć zdolność komórek do migracji, to wydajniej 
będą one uczestniczyć w regeneracji mięśnia. W tych badaniach wykorzystałem mysie ESC 
oraz mysie mioblasty uzyskane z komórek satelitowych. Wykazałem, że ESC mają bardzo 
ograniczoną zdolność do zasiedlania mięśnia, jednak stymulacja Sdf-1 powoduje ich 
wydajniejszą migrację wzdłuż włókien mięśniowych. ESC niestymulowane Sdf-1 oraz te,  
w których wyciszono ekspresję Cxcr4, formowały agregaty i nie rozprzestrzeniały się w obrębie 
regenerującego mięśnia. Wyciszenie ekspresji Cxcr7 nie wpływało na zdolność komórek  
do migracji. Ten wynik potwierdził wcześniejsze obserwacje na temat wpływu Sdf-1 na ESC 
w hodowli mieszanej z mioblastami. Następnie wykazałem, że mioblasty podane do 
regenerującego mięśnia są zdolne do współtworzenia włókien mięśniowych. Stymulacja Sdf-1 
zwiększa odsetek włókien, w skład których wchodziły badane mioblasty. Ich odróżnienie było 
możliwe dzięki bakteryjnej β-galaktozydazy obecnej w przeszczepianych mioblastów, które 
były izolowane z transgenicznej myszy. Podobnie jak w przypadku ESC wyciszenie poziomu 
ekspresji Cxcr4 powodowało zmniejszenie zdolności do migracji, a w konsekwencji mniejszy 
odsetek włókien hybrydowych. Cxcr7 nie był zaangażowany w ten proces. Warto jednak 
zauważyć, że dostarczenie białka Sdf-1 bezpośrednio do mięśnia, skuteczniej indukowało 
uczestniczenie przeszczepionych komórek w współtworzeniu nowych włókien mięśniowych 
niż preinkubacja komórek z Sdf-1 przed ich przeszczepieniem do mięśnia. Świadczy to więc  
o tym, że najistotniejsze jest, aby komórki były wystawione na działanie Sdf-1 w trakcie 
migracji i fuzji.  
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ABSTRACT
The skeletal muscle regeneration occurs due to the presence of tissue specific stem cells - satellite
cells. These cells, localized between sarcolemma and basal lamina, are bound to muscle fibers
and remain quiescent until their activation upon muscle injury. Due to pathological conditions,
such as extensive injury or dystrophy, skeletal muscle regeneration is diminished. Among
the therapies aiming to ameliorate skeletal muscle diseases are transplantations of the stem
cells. In our previous studies we showed that Sdf-1 (stromal derived factor ¡1) increased
migration of stem cells and their fusion with myoblasts in vitro. Importantly, we identified that
Sdf-1 caused an increase in the expression of tetraspanin CD9 - adhesion protein involved in
myoblasts fusion. In the current study we aimed to uncover the details of molecular mechanism
of Sdf-1 action. We focused at the Sdf-1 receptors - Cxcr4 and Cxcr7, as well as signaling
pathways induced by these molecules in primary myoblasts, as well as various stem cells -
mesenchymal stem cells and embryonic stem cells, i.e. the cells of different migration and
myogenic potential. We showed that Sdf-1 altered actin organization via FAK (focal adhesion
kinase), Cdc42 (cell division control protein 42), and Rac-1 (Ras-Related C3 Botulinum Toxin
Substrate 1). Moreover, we showed that Sdf-1 modified the transcription profile of genes
encoding factors engaged in cells adhesion and migration. As the result, cells such as primary
myoblasts or embryonic stem cells, became characterized by more effective migration when
transplanted into regenerating muscle.
KEYWORDS
embryonic stem cells;
mesenchymal stem cells;
migration; mobilization;
muscle regeneration;
myoblasts
Introduction
The skeletal muscle regeneration occurs due to the presence
of stem cells called satellite cells (SCs) that are localized
between sarcolemma and basal lamina. The role of SCs in
skeletal muscle repair is unquestionable (reviewed in ref. 1).
Unfortunately, due to aging, extensive damages or various
pathological states, for example muscular dystrophy, muscle
reconstruction is diminished.2-4 Stem cells transplantation
belongs to the therapeutic approaches aiming to improve
muscle regeneration (reviewed in ref. 5). In the initial stud-
ies, focusing on the skeletal muscle cell therapies, SCs and
primary myoblasts, due to their natural function, were the
first choice of cells tested (reviewed in refs. 6, 7). Under
physiological conditions, after muscle injury, SCs become
activated what leads to the cell cycle re-entry, proliferation,
and finally their differentiation into myoblasts that fuse and
reconstruct myotubes and then muscle fibers. In the 80s of
XX century Partridge and collaborators documented that
wild-type myoblasts injected to muscle of dystrophic mice
(mdx mice) were able to reconstruct muscle fibers and
restore the dystrophin synthesis.8 As demonstrated later, the
improvement in the skeletal muscle regeneration was
observed after transplantation of undifferentiated, purified
satellite cells population, rather than satellite cells derived
myoblasts.9,10 In the 90s many clinical trials based on the
model described by Partridge were conducted, however, the
results were not satisfactory (reviewed in refs. 6, 11). Trans-
planted cells were able to participate in themuscle regenera-
tion and partially restore dystrophin expression but no
functional long-term improvement was observed.12-14
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Themost important obstacles in myoblast transplantation
include specific immune response against transplanted cells,
limited migration within the muscle, and massive apoptosis
of transplanted cells (reviewed in refs. 7, 15, 16). The limited
migration ability of transplanted myoblasts was shown in
many studies.17-20 Thus, many lines of evidence documented
that injectedmyoblasts accumulate within the site of injection
and only few reports showed that they could migrate up to
1 cm in depth from the monkey (Macaca mulata) muscle
surface.21 Importantly, co-injected growth factors such as
bFGF (basic fibroblast growth factor) and IGF-1 (insulin like
growth factor), improved migration of monkey (Macaca
mulata) myoblasts transplanted into biceps brachii. However,
myofibers formed with the participation of these cells were
detectable only near the injection site. Moreover, analyzed
myoblasts were not able to fuse with undamaged muscle
fibers, regardless of the growth factors used.22 In our own
studies we showed that the Sdf-1 could improve migration of
satellite cell derived myoblasts and C2C12 myoblasts in vitro
in metalloproteinase (MMP) dependent manner.23 We also
documented that Sdf-1 treatment enhanced embryonic stem
cells (ESCs) and bone marrow derived mesenchymal stem
cells (BM-MSC) migration and fusion with myoblasts in
vitro, what was connected with the increase in tetraspanin
CD9 expression.24
In the current study we investigated which molecular
pathways induced by Sdf-1 lead to the increased migra-
tion. We hypothesized that stimulation of transplanted
cells migration using Sdf-1 improves their ability to par-
ticipate in muscle repair. To verify this hypothesis we
analyzed various stem cell populations - mouse primary
myoblasts derived from SCs, human mesenchymal stem
cells isolated from umbilical cord connective tissue, i.e.,
Wharton’s jelly (WJ-MSCs), and mouse embryonic stem
cells (ESCs). Our choice based on the previous studies in
that we documented that these stem cells are able to
undergo myogenic differentiation and also to participate
in the skeletal muscle regeneration.24-26
Multipotent mesenchymal stem cells (MSCs) could be
derived from different sources, such as bone marrow, adi-
pose tissue,Wharton jelly (umbilical cord connective tissue),
umbilical cord blood, skin, dental pulp, spleen, lung, and
also skeletal muscles (reviewed in refs. 27, 28). Various pop-
ulations of mesenchymal stem cells were able to improve
skeletalmuscle reconstruction.29-31Myogenic differentiation
of the pluripotent stem cells, such as embryonic stem cells
(ESCs), which are characterized by unlimited potential to
proliferate and ability to differentiate into any given tissue,
has been also documented (reviewed in refs. 32, 33). An effi-
cient protocol allowing derivation of myoblasts from ESCs,
based on the supplementation of culture medium with fac-
tors inducing mesoderm formation and myogenic differen-
tiation, was proposed only recently and obtained myoblasts
were tested both in vitro and in vivo.34 Cells derived from
ESCs when transplanted into tibialis anterior muscles of
mdxmice were able to formmuscle fibers and also to differ-
entiate into Pax7-expressing cells that resembled SCs.34
However, methods improving homing of these cells to the
site of the injury via improvement of their migration are still
not readily available.
In the current study we compared the reaction of pri-
mary myoblasts, WJ-MSC, as well as ESCs to Sdf-1 treat-
ment, which—as we previously shown—is a potent
factor improving skeletal muscle regeneration.23,24 First
we analyzed changes in transcription profile and the sig-
naling pathways engaged in stem cells response to Sdf-1
treatment. Next, we concentrated on the role of Sdf-1
receptors i.e. CXCR7 and CXCR4 in stem cells migration
both in vitro and in vivo. Then, we examined if Sdf-1
pretreatment of stem cells with Sdf-1 or co-injection of
these cytokine could improve participation of tested cells
in the skeletal muscle regeneration.
Materials and methods
All the experiments were performed with the approval of
Local Ethical Commission No 1 in Warsaw – permission
no 240/2012.
Cells cultures
Satellite cells – derived myoblasts (primary myoblasts)
Satellite cells were isolated from the gastrocnemius muscles
of 3months old C57Bl6Nmalemice carrying the lacZ trans-
gene in the ROSA26 locus. Mice were sacrificed by cervical
dislocation. Muscle fibers were isolated according to previ-
ously described protocol.35 Briefly, muscles were dissected
and digested with 0.2% collagenase type I (Sigma-Aldrich)
inDulbecco’s modified Eagle’s medium (DMEM, Life Tech-
nologies) at 37C in 5% CO2 for 60min. Next, single muscle
fibers were transferred to DMEM containing 10% horse
serum (HS, Life Technologies) and 1% penicillin/streptomy-
cin antibiotics (AB, Life Technologies). Suspension of mus-
cle fibers was passed through a syringe needle (21G) and
cleared by filtration through 40 mm cell strainer. Obtained
satellite cells were plated in 6-well culture dishes coated with
Matrigel Matrix Growth Factor Reduced (BD Biosciences).
Primary myoblasts were maintained in so called “growth
medium,” i.e., DMEM supplemented with 20% fetal bovine
serum (FBS), 10% HS, 0.5% chicken embryo extract (CEE,
Life Technologies) and 1% AB.
Mesenchymal stem cells derived from Wharton jelly
(WJ-MSCs)
WJ-MSCs were kindly provided by prof. Zygmunt Pojda
(Department of Molecular and Translational Oncology,
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Maria Sk»odowska-Curie Memorial Cancer Center and
Institute of Oncology, Warsaw, Poland). WJ-MSCs were
seeded and cultured in DMEM (Life Technologies) supple-
mented with 15% heat inactivated FBS (hiFBS) and 1% AB.
Mouse embryonic stem cells (ESCs)
ESCs constitutively expressing histone H2B-GFP were pro-
vided by Dr. Kat Hadjantonakis.36 Mitomycin-inactivated
mouse embryonic fibroblasts (MEFs), that served as feeder
layer for ES cells, were plated on 1% gelatin coated culture
dishes (Sigma-Aldrich) and cultured in DMEM supple-
mented with 10% FBS and 1% AB. Twenty four hours later
ESCs were seeded onto the inactivated MEFs and cultured
in knockout DMEM (Life Technologies) supplemented
with 10% serum replacement (SR, Life Technologies),
0.1 mM nonessential amino acids (Sigma-Aldrich), 2 mM
L-glutamine (Life Technologies), 0.1 mM b-mercaptoetha-
nol (Sigma-Aldrich), 1%AB, and 500U/ml leukemia inhibi-
tory factor (LIF, Chemicon). Prior to transfection with
siRNA, ESCs were separated fromMEFs by pre-plating and
cultured in cultured dishes coated with 10%MatrigelMatrix
Growth Factor Reduced (BD Biosciences) in DMEM until
the time of further manipulations.
Morphological analyses
The morphology of primary myoblasts, WJ-MSCs, and
ESCs was analyzed using Nikon Eclipse TE200 micro-
scope equipped with Hoffman contrast.
Cells transfection
Primary myoblasts, WJ-MSCs, and ESCs were plated
into culture dishes and after reaching 50-60% of conflu-
ency transfected with Silencer Select Pre-designed siRNA
(Life Technologies) complementary to mRNAs encoding
either Cxcr4 (ID:s64091) or Cxcr7 (ID:s64124). Appro-
priate negative control siRNA was used according to
manufacturer’s recomendation. siRNA duplexes were
diluted in DMEM to 100 pmol concentration and Lipo-
fectamine RNAiMAX (Life Technologies) was added
according to manufacturer’s instructions. The Sdf-1
(10 ng/ml) was added 24 h after transfection. The cells
were collected 48 h post-Sdf-1 treatment and processed
either for mRNA isolation, followed by qRT-PCR,
immunolocalization, Western blotting, G-LISA or for
transplantation into injured and regenerating gastrocnie-
mus muscles. The efficiency of CXCR4 or CXCR7 down
regulation was assessed by qRT-PCR and Western-blot.
Quantified real time PCR (qRT-PCR)
Total RNA was isolated from primary myoblasts, WJ-
MSCs, and ESCs using mirVana Isolation Kit (Life
Technlogies), according to the manufacturer’s protocol.
RNA was extracted from biological triplicates (3 indepen-
dent cell cultures per each experiment). 250 ng of RNA
from each sample was reverse-transcribed using the Super-
Script II Reverse Transcriptase (Life Technologies) accord-
ing to the manufacturer’s protocol. Next, mRNA levels were
examined using Quantitative real-time PCR analysis
(qPCR) with TaqMan assays (Life Technologies) for the
following genes: CXCR4 [Mm01996749], CXCR7
[Mm02619632], Rac-1 [Mm01331626], Cdc42
[Mm01194005], focal adhesion kinase (FAK)
[Mm00552827], and actin [Mm01268569]. Hypoxanthine
phosphoribosyltransferase 1 (Hprt1) [Mm01545399] was
used as the reference gene. All reactions were performed in
triplicates. qPCR was performed with the TaqMan Gene
Expression Master Mix (Life Technologies) using LightCy-
cler 480 (Roche Applied Sciences) according to manufac-
turer’s instruction. The conditions of RT-qPCR were as
follows: reverse transcription: 25C for 10 min, 42C for
60 min, 85C for 5 min, qPCR: 50C for 2 min, template
denaturation 95C for 10 min, 45 cycles of 95C for 15 sec
and 60C for 60 sec. Threshold-cycle (Ct) values of the ana-
lyzed amplicons were determined with LightCycler 480
Software (Roche Applied Science). Expression levels were
calculated with 2-(DCT) formula using relative quantification
tool in LightCycler 480 Software. Expression levels
and standard deviations for each gene was visualized as
the column charts using GraphPad Software (La Jolla,
CA, USA). Reference gene Hprt1 displayed high expres-
sion stability. Results were analyzed using using Graph-
Pad Software and non-paired t-test was performed to
compare treated with the control cells. The differences
were considered statistically significant when p < 0.05
(marked with asterisks).
Cell proliferation assay
Primary myoblasts, WJ-MSCs, and ESCs were incubated
in 0.5 mM carboxyfluorescein succinimidyl ester (CFSE,
Life Technologies) in PBS at 37C for 10 min. Cells were
rinsed in PBS and cultured for 2 days in the culture
medium appropriate for each cell type, under standard
conditions. Next, cells were rinsed in PBS and subjected
to flow cytometry analysis (BD FACSCALIBUR, BD Bio-
sciences) using CellQuestPro software. Unlabeled cells
(negative control) and cells analyzed directly after label-
ing with CFSE (positive control) were included into each
experiment. Three independent experiments were per-
formed. Results were analyzed using GraphPad Software
and non-paired t-test was performed to compare treated
with the control cells. The differences were considered
statistically significant when p < 0.05 (marked with
asterisks).
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Migration assay
Migration of myoblasts, WJ-MSCs, and ESCs was analyzed
using scratch wound healing assay.37 Briefly, cells were
plated in the culture dish and cultured until they reached
90% of confluency. Next, the cells were scratched from the
plate using plastic tip to create the “wound.” The wound
healing manifested by the ability of the cells to refill the
created gap was monitored after 48h of culture. Three
independent experiments were performed. Results were
analyzed using using GraphPad Software and non-paired
t-test was performed to compare treated with the control
cells. The differences were considered statistically signifi-
cant when p < 0.05 (marked on charts with asterisks).
Analysis of Rac-1 and Cdc42 activity
Primary myoblasts, ESCs and WJ-MScs were cultured as
described above. Thirty min after Sdf-1 treatment cells
were lysed in culture dishes, lysates collected and frozen
in liquid nitrogen. Active Cdc42 and Rac-1 were ana-
lyzed using the G-LISA activation assay kit (Cytoskele-
ton, Inc.) according to the manufacturer’s instructions.
The chemiluminescence signal was detected using the
mQuant (Biotek Instruments) microplate reader. Three
independent experiments were performed. Results were
analyzed using GraphPad Software and non-paired t-test
was performed to compare treated with the control cells.
The differences were considered statistically significant
when p < 0.05 (marked on charts with asterisks).
Microarray analysis
ESCs were cultured and either treated with Sdf-1 or
transfected with Silencer Select Pre-designed siRNA (Life
Technologies) complementary to mRNAs encoding
either CXCR4 (ID:s64091) or CXCR7 (ID:s64124) as
described above. Total RNA was isolated using mirVana
Isolation Kit (Life Technlogies). Next, its integrity was
checked with 2100 Bioanalyzer (Agilent Technologies)
using RNA 6000 NAno LAb Chip kit (Agilent Technolo-
gies). All RNA samples had integrity number above 8.5.
100 ng of total RNA for each sample was biotin labeled
with the TargetAmpTM-Nano Labeling Kit for Illumina
Expression BeadChip (Epicentre Biotechnologies).
Labeled RNA was purified with RNeasy MinElute
Cleanup Kit (Qiagen) and hybridized onto MouseRef-8
v2.0 Expression BeadChip (Illumina Inc.) according to
manufacturer’s instructions. Arrays were scanned with
an HiScanSQ System (Illumina Inc.). Raw data were
imported to GenomeStudio (Illumina) and the average
signal intensities were analyzed in Partek Genomic Suite
(Partek, Inc.) v. 6.6 after quantile normalization and Log2
transformation. Qualitative analysis was performed, e.g.
Principal Component Analysis, in order to identify out-
liers and artifacts on the microarray. After quality check
the 2-way ANOVA (Analysis of Variance) model by
using Method of Moments38 was performed on the data
and lists of significantly and differentially expressed
genes between biological variants (with the cutoff values:
p-value < 0.05, ¡1.3>Fold Change>1.3) were created.
Fisher’s Least Significant Difference (LSD) was used as
the contrast method39 to compare: ES-Cxcr4 (ESCs trans-
fected with siRNA complementary to CXCX4 mRNA) vs
ES-Sdf-1 (ESCs treated with Sdf-1) and ES-Cxcr7 (ESCs
transfected with siRNA complementary to CXCX7
mRNA) vs ES-Sdf-1. Unsupervised hierarchical clustering
was performed on the selected lists to in order to find
genes and samples with similar profiles. Gene networks
were created by interposing the results onto the database
of Ingenuity containing information about gene functions
with the use if Ingenuity Pathway Analysis tool.
Muscle injury and cells transplantation
To induce regeneration of skeletal muscles, 3-month old
male BALB/c mice were anesthetized and their gastrocnie-
mus muscles were injected with 50 ml of cardiotoxin (CTX)
from Naja mossambica (10 mM in PBS, Sigma-Aldrich).
After the procedure mice were kept under standard condi-
tions with free access to food and water. Twenty four hours
later control cells, Sdf-1 treated cells, or cells in that expres-
sion of Cxcr4 or Cxcr7 was silenced were injected into
injured muscles. The number of transplanted cells varied,
i.e. 0.5 million of myoblasts, 0.2 million of WJ-MSCs or
1 million of ESCs, suspended in 50 ml of PBS, was trans-
planted. Moreover, regenerating gastrocnemius muscle was
injected with Sdf-1 (100 ng per 20 ml of 0.9% NaCl ) or
20 ml of 0.9% NaCl (saline treated muscles served controls).
Sdf-1 and NaCl was injected at the opposite ends of the
muscles than the transplanted cells. After 7 or 14 d after
injury, i.e., days of regeneration, muscles were dissected and
analyzed (immunocytochemistry and histochemistry).
Localization of transplanted cells within the muscle was
based on the expression of appropriate markers. Satellite
cells, from which primary myoblasts were derived, were iso-
lated from 3-month old C57Bl6N male mice carrying the
lacZ transgene in the ROSA26 locus. WJ-MSCs were local-
ized on the basis of human nuclear antigen. ESCs were local-
ized on the basis of the expression of H2B-GFP.
Immunocytochemistry
Selected antigens were immunolocalized in in vitro cultured
cells, isolated at day 7 of regeneration muscle fibers, as well
as in muscle sections (cross and longitudinal). Cells or iso-
lated muscle fibers were fixed with 3% PFA for 10 min,
washed with PBS and stored in 4C. Muscles were dissected
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7 or 14 d after injury and cells transplantation. They were
frozen in isopentane cooled with liquid nitrogen, transferred
into¡80C, and cut into 7 mm-thick sections with cryomi-
crotome (Microm HM505N) and stored in 4C. Cryosec-
tions were hydrated in PBS, fixed in 3% PFA, and washed
with PBS. To obtain longitudinal sections dissected muscles
were fixed with Bouin’s solution, dehydrated and embed
into paraffin blocks. Paraffin blocks were cut for 9mm-thick
slices and placed on covered with 0.5% gelatin in water glass
slides and then dried in 40C. Paraffin sections were stored
in 4C and rehydrated before immunolocalization.
Next, cells or muscle sections were permeabilized with
0.1% Triton X-100/PBS (Sigma-Aldrich), and incubated
with 0.25% glycine (Sigma-Aldrich). Non-specific binding
of antibodies was blocked with 3% bovine serum albumin
(BSA, Sigma-Aldrich) supplementedwith 2% donkey serum
(Sigma-Aldrich) in PBS, at room temperature, for 1h. Next,
samples were incubated for 2 h with primary antibodies
diluted 1:100 in 3% BSA in PBS, overnight, washed with
PBS, and incubated at room temperature with secondary
antibodies diluted 1: 200 in 1.5 % BSA in PBS. After washing
with PBS, cell nuclei were visualized by incubation with
DraQ5 (Biostatus Limited) diluted 1:1000 in PBS for
10 min. Specimens were mounted with Fluorescent Mount-
ing Medium (Dako Cytomation). After the procedure was
completed samples were analyzed using confocal micro-
scope Axiovert 100M (Zeiss) and LSM 510 software. The
following primary antibodies were used: chicken polyclonal
anti-b-galactosidase (Abcam), mouse monoclonal anti-
human nuclear antigen (Abcam), mouse monoclonal anti-
Green Fluorescent Protein (GFP) (Abcam), rabbit
polyclonal anti-Myod1 (Abcam), mouse monoclonal anti-
Cdc42 (SantaCruz Biotechnology), rabbit polyclonal anti-
Rac-1 (SantaCruz Biotechnology), rabbit polyclonal
anti-FAK (SantaCruz Biotechnology), and rabbit polyclonal
anti-laminin (Sigma-Aldrich). The following secondary
antibodies were used: anti-mouse igG Alexa Fluor 488, anti-
rabbit igG Alexa Fluor 566, anti-rabbit igG Alexa Fluor 488,
and anti-chicken igG Alexa Fluor 488. All secondary anti-
bodies were purchased from Life Technologies. Actin cyto-
skeleton was localized using falloidin conjugated with
TRITC (Sigma). Three independent experiments were
performed for each analysis.
Western blotting
Proteins were isolated from cells or gastrocnemius muscles
using cOmplete Lysis-M EDTA-free kit (Roche Applied Sci-
ence). Twenty-fivemg of total protein lysate were denatured
by boiling in Laemmli buffer, separated using SDS-Page
electrophoresis, and transferred to PVDF membranes
(Roche Applied Science). The membranes were blocked
with 5% Blotto (BioRad)/TBS for 1h and incubated with
primary antibodies diluted 1:2000 in 5% Blotto (BioRad)/
TBS, at 4C, overnight, followed by secondary antibodies
diluted 1:20000, at room temperature, for 2 h. Next, protein
bands were visualized with SuperSignalWest Pico Chemilu-
minescent Substrate (Thermo Scientific) and exposed to
chemiluminescence positive film (Amersham Hyperfilm
ECL, GE Healthcare). The obtained results were analyzed
with GelDoc2000 using Quantity One software (BioRad).
The density of examined bands was compared to density of
tubulin bands. The following primary antibodies were used:
rabbit polyclonal anti-Cxcr4 (Abcam), rabbit polyclonal
anti-Cxcr7 (Abcam), rabbit polyclonal anti-pFAK (Cell
Signaling), rabbit polyclonal anti-FAK (SantaCruz Biotech-
nology), mouse monoclonal anti-Cdc42 (SantaCruz Bio-
technology), rabbit polyclonal anti-Rac-1 (SantaCruz
Biotechnology), mouse monoclonal anti-actin (Abcam),
and mouse monoclonal anti-tubulin (Sigma-Aldrich). Sec-
ondary antibodies used were: peroxidase-conjugate rabbit
anti-mouse igg (Sigma-Aldrich) and peroxidase-conjugate
goat anti-rabbit igg (Sigma-Aldrich). Three independent
experiments were performed.
Flow cytometry analysis
Gastrocnemius muscles that received ESCs constitutively
expressing histone H2B-GFP were isolated at day 7 and 14
of regeneration. Next, they were digested with 0.15% pro-
nase (SigmaAldrich) inHam’s F12medium (Life Technolo-
gies) buffered with 10 mM HEPES (Life TEchnolofies),
containing 10% fetal calf serum (FCS), at 37C, for 1.5 h.
Obtained cell suspension was filtered through 40 mm cell
strainer. Then, cells were fixed in a 3% PFA in PBS, washed
with PBS, and analyzed with FACSCalibur (Becton-Dickin-
son) equipped with a 488-nm argon laser to detect GFP sig-
nal. The cells were also incubated with rabbit polyclonal
anti-Myf5 antibody (Abcam) diluted in 3% BSA in PBS
1:100, at room temperature, for 1 h, followed by secondary
antibody anti-rabbit igG Alexa Fluor 566. Three data
parameters were acquired and stored: FSC, SSC and fluores-
cence 1 – FL1 (fluorescein isothiocyanate, FITC). CellQuest
application, version 1.2, was used for the analysis. Three
independent experiments were performed. Results were
analyzed GraphPad Software and non-paired t-test was
performed to compare treated with the control cells. The
differences were considered statistically significant when
p< 0.05 (marked on charts with asterisks).
Results
Sdf-1 induces stem cells migration but
not proliferation
We analyzed primary myoblasts, WJ-MSCs, or ESCs which
were treated with Sdf-1 alone or transfected with siRNA
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complementary to mRNAs encoding either Cxcr4 or Cxcr7
and treated with Sdf-1, along with control, i.e. untreated
cells. The Cxcr4 or Cxcr7 silencing assessed at mRNA level
was proved to be efficient. siRNA complementary to Cxcr4
mRNAdecreased the level of this transcript to 28%C/¡ 8%
in primary myoblasts, 49% C/¡ 16% in WJ-MSCs, and to
34% C/¡ 8% in ESCs, as compared to control, i.e., cells of
each type that where neither treated with Sdf-1 nor trans-
fected with siRNAs (Fig. 1A). siRNA complementary to
mRNA encoding Cxcr7 decreased the level of Cxcr7 tran-
scripts to 34% C/¡ 11% in primary myoblasts, 38% C/¡
18% inWJ-MSCs and 41%C/¡ 13% in ESCs, as compared
to control (Fig. 1A). Sdf-1 treatment did not significantly
change the level of Cxcr4 or Cxcr7 mRNA (Fig. 1A). The
changes in CXCR4 and CXCR7 level in treated cells were
also pronounced at protein level (Fig. 1B).
Scratch migration assay revealed that in the response
to Sdf-1 gradient primary myoblasts, WJ-MSC and ESCs
migrate more effectively (Fig. 2A). Migration of all types
of examined cells depended on Cxcr4 receptor - silencing
of its expression decreased this process (Fig. 2A). Cxcr7
silencing did not significantly impact at the cell migra-
tion in performed assay. Next, we tested whether Sdf-1
controls the ability of primary myoblasts, WJ-MSCs, and
ESCs to proliferate. CFSE test allowed us to estimate the
proportion of cells that did not divide, divided once or
more than twice. It proved that Sdf-1 treatment did not
change myoblasts, WJ-MSCs, as well as ESCs prolifera-
tion rate. Neither Cxcr4 nor Cxcr7 expression silencing
affected primary myoblasts and WJ-MSCs divisions
(Fig. 2B). Interestingly, Cxcr7 silencing significantly
increased ESCs proliferation (Fig. 2B).
The signaling pathways in actin organization in
stem cells after Sdf-1 treatment
Next, we analyzed the changes in actin cytoskeleton organi-
zation and which signaling pathways were involved in the
activation of the analyzed cells migration in the response to
Sdf-1. We chose to analyze Cdc42 (cell division control pro-
tein 42), Rac-1 (Ras-Related C3 Botulinum Toxin Substrate
1), and focal adhesion kinase (FAK), i.e. the factors known
to participate in the processes associated with cell migration
such as actin polymerization and focal contacts forma-
tion.40-42 After Sdf-1 stimulation themorphology of the cells
and organization of actin cytoskeleton changed, i.e., all ana-
lyzed cells formed numerous stress fibers and filopodia
(Fig. 3A). In Sdf-1 treated cells the actin filaments were
more abundant (Fig. 3A). This effect was reversed by Cxcr4
silencing, what correlated with the decrease in actin expres-
sion at mRNA and protein levels (Fig. 3B and C). The SCs
and WJ-MSCs in that Cxcr4 expression was silenced were
Figure 1. The Cxcr4 and Cxcr7 level in in vitro cultured primary myoblasts, WJ-MSCs, and ESCs 48h after transfection with siRNA and Sdf-1 treat-
ment. (A) The level of mRNA encoding Cxcr4 and Cxcr7. Obtained data is presented as mean§ standard deviation. Student’s non-paired t-test
was used for statistical analyses. Asterisk marks significant differences (P< 0.05). (B) Western blotting of Cxcr4, Cxcr7, and tubulin.
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characterized by changes in Cdc42, Rac-1 and FAK localiza-
tion (Fig. 3D and E).
However, Sdf-1 did not impact at the levels of Cdc42,
Rac-1, and FAK proteins in primary myoblasts, WJ-MSCs,
or ESCs (Fig. 4A). Silencing of Cxcr4 or Cxcr7 expression
slightly decreased the level of Cdc42 protein (Fig. 4A).
Importantly, Sdf-1 caused the significant changes in the
activity of studied proteins (Fig. 4A and B). The activity of
Cdc42 and Rac-1 GTPases was higher in Sdf-1 treated myo-
blasts, WJ-MSCs, and also ESCs, as compared to the
untreated cells (Fig. 4B). Silencing of Cxcr4 but not Cxcr7
abolished the impact of Sdf-1 at the activity of Cdc42 and
Rac-1 GTPases. As far as active, phosphorylated form of
FAK (pFAK), is concerned it was detectable in control myo-
blasts, WJ-MSCs, and ESCs (Fig. 4A). Sdf-1 caused increase
in the level of pFAK in myoblasts andWJ-MSCs, but not in
ESCs. However, in all studied cell types the effect of Sdf-1 on
FAK phosphorylation was lost when expression of both its
receptors, i.e. Cxcr4 and Cxcr7, was silenced (Fig. 4A).
Changes in transcription profile in ESCs after
Sdf-1 treatment
To analyze the changes in the transcriptome provoked by
Sdf-1 we decided to use ESCs because in these cells the
changes in morphology and cytoskeleton organization was
the best pronounced after Sdf-1 treatment. mRNA isolated
from control ESCs, as well as cells that were Sdf-1 treated,
Sdf-1 treated and transfected with siRNA complementary
to mRNAs encoding either Cxcr4 or Cxcr7, was analyzed
using microarray technique (Fig. 5). Analysis of variance
(ANOVA) allowed to create lists of genes significantly
changed in ESCs that were Sdf-1 treated and transfected
with appropriate siRNA, as compared to cells treated only
with Sdf-1 (with the cutoff values: p-value< 0.05,
¡1.3>Fold Change>1.3). This analysis revealed that Sdf-1,
acting via Cxcr4 receptor, regulates the expression of 90
transcripts, while acting via Cxcr7 receptor affects the
expression of 113 transcripts (Fig. S1). Using Ingenuity
Pathway Analysis we showed that Sdf-1 impacts at the
expression ofmany genes encoding proteins engaged in cells
adhesion and migration (Fig. 5), including transcripts
encoding proteins engaged directly or indirectly in actin and
adhesion proteins expression. Sdf-1 acting via Cxcr4, but
not Cxcr7, regulates the expression of mRNA encoding
adhesion proteins such as tetraspanin CD9 and ADAM9 (a
disintegrin and metalloproteinase 9). Sdf-1 acting via Cxcr4
influences the expression of transcripts encoding cytoskele-
ton proteins present in skeletal muscle fibers, such as actin
or a actin (ACTA1). Activation of this signaling pathway
also induced the expression of calpain small subunit 1
(CAPNS1) that belongs to the family of calcium-dependent,
non-lysosomal cysteine proteases. Sdf-1 acting via Cxcr7
impacted the levels of mRNAs encoding F-actin and
ACTA1. It also reduced the expression of mRNAs encoding
calpains, such as calpain 5 (CAPN 5) and CAPNS1. Sum-
marizing, transcriptome analysis confirmed important role
of Sdf-1 in the activation ofmigration and allowed us to pin-
point and distinguish the targets of pathways activated by
Sdf-1 binding to Cxcr4 or Cxcr7.
Regeneration of injured skeletal muscles treated
with Sdf-1 and stem cells
Next, we decided to analyze if Sdf-1 pretreatment of trans-
planted cells or Sdf-1 co-injection with transplanted cells
Figure 2. Sdf-1 impact at in vitro cultured primary myoblasts, WJ-MSCs, and ESCs migration and proliferation. (A) Proportion of invaded
area calculated from the results of scratch wound assay. Analysis was performed at day second after the scratch wound formation. (B)
Results of CFSE test documenting the proliferation rate of studied cells. Analysis was performed after 2 d of culture subsequently CFSE
staining. Obtained data is presented as mean § standard deviation. Student’s non-paired t-test was used for statistical analyses. Asterisk
marks significant differences (P < 0.05).
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could improve participation of stem cells in muscle regener-
ation. Again we also focused at the role of Cxcr4 and Cxcr7
in the migration of tested cells in regenerating muscle. Con-
trol, i.e., untreated primary myoblasts, WJ-MSCs, or ESCs,
as wells as cells treated with Sdf-1 alone or treated with Sdf-
1 and transfected with siRNA complementary to mRNAs
encoding either Cxcr4 or Cxcr7 were transplanted to control
muscles injectedwith 0.9%NaCl (saline) ormuscles injected
with Sdf-1 in 0.9% NaCl (Fig. 6). Onemuscle of eachmuscle
pair was injectedwith saline, while another, i.e. contralateral,
with Sdf-1. Importantly, Sdf-1 was injected at the opposite
end of themuscle in the relation to the site of cells transplan-
tation (approximately 1 cm distance). Sdf-1 was co-injected
with transplanted cells.
First, we focused at the morphology of all groups of
treated muscles, followed the localization of transplanted
cells, as well as, the efficiency of their migration and muscle
homing (Fig. 7). Primary myoblast were identified as
Figure 3. Sdf-1 impact at actin, FAK, Rac-1 and Cdc42 in in vitro cultured primary myoblasts, WJ-MSCs, and ESCs. (A) Immunolocalization
of actin (red - actin, blue - chromatin). (B) The level of mRNA encoding actin. Obtained data is presented as mean § standard deviation.
Student’s non-paired t-test was used for statistical analyses. Asterisk marks significant differences (P < 0.05). (C) Western blotting of
actin in ESCs. (C) Localization of FAK, Rac-1 and Cdc42 in primary myoblasts (blue – chromatin, red – immunolocalization of actin, green
– immunolocalization of studied proteins). (D) Localization of FAK, Rac-1 and Cdc42 in WJ-MSCs (blue – chromatin, red – immunolocali-
zation of actin, green – immunolocalization of studied proteins).
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b-galactosidase positive cells, humanWJ-MSCs on the basis
of human nuclear antigen immunolocalization, and ESCs
on the basis of histone H2B-GFP fluorescence. The effi-
ciency of the participation of transplanted cells in themuscle
regeneration was assessed on the basis of the number of cells
able to home injured muscle and/or to form new muscle
fibers. Transplanted primary myoblasts formed new muscle
fibers with the highest efficiency, as compared to other cells
analyzed (Fig. 7A and B). Control primary myoblasts trans-
planted to muscles injected with saline participated in the
formation of 4.7% C/¡ 3% muscle fibers. In Sdf-1 treated
muscles this proportion reached 8.2% C/¡ 3.5%. Finally,
Sdf-1-treated myoblasts injected to Sdf-1-injected muscles
participated in the formation of 12.1% C/¡ 5.5% fibers
(Fig. 7A and B). Silencing of Cxcr4 expression significantly
decreased the number of myofibers formed with the partici-
pation of transplanted myoblasts (Fig. 7B). Silencing of
Cxcr7 expression did not significantly change the number
of myofibers formed with the participation of transplanted
myoblasts (Fig. 7B). Thus, co-injection of myoblasts and
Sdf-1 improved participation of myoblast in formation of
newmyofibers.
TheWJ-MSCs transplanted into injuredmuscles, control
or Sdf-1 injected, only very rarely were found within regen-
erating tissue. Only few of them were able to participate in
formation of new muscle fibers (data not shown). On the
other hand, ESCs were able to home regenerating tissue and
were easily detectable betweenmuscle fibers. However, these
cells also only very rarely were found to participate in the
formation of muscle fibers. In control, saline-injected
muscles most of the control, untreated ESCs formed aggre-
gates surrounded with muscle fiber basal lamina. Only sin-
gle cells were localized along basal lamina. The localization
of ESCs changed when muscles were injected with Sdf-1.
Under such conditions ESCs were able to migrate and local-
ize along muscle fiber basal lamina. In this case they very
Figure 4. Sdf-1 impact at FAK, Rac-1 and Cdc42 level and activation in vitro cultured primary myoblasts, WJ-MSCs, and ESCs. (A) Western
blotting of Cxcr4, Cxcr7, FAK, phosphorylated FAK (pFAK), Rac-1, Cdc42, and tubulin. (B) The activity of Rac-1 and Cdc42 in primary
myoblasts, WJ-MSCs and ESCs. Obtained data is presented as mean § standard deviation. Student’s non-paired t-test was used for
statistical analyses. Asterisk marks significant differences (P < 0.05).
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Figure 5. Sdf-1 impact at global gene expression in in vitro cultured ESCs. (A) Transcription profile of genes in ESCs. Blue color indicates
low and red color indicates high expression levels of mRNA transcripts. (B) Gene networks created by interposing the results onto
database of Ingenuity containing information about the gene function with the use of Ingenuity Pathway Analysis tool.
Figure 6. The experimental design of in vivo analyses.
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Figure 7. The localization of primary myoblasts and ESCs after transplantation to injured gastrocnemius muscle. (A) The localization of trans-
planted primary myoblasts expressing b-galactosidase in cross section of muscle at day 7 of regeneration (green - b-galactosidase, blue – chro-
matin, red – immunolocalization of laminin). (B) The proportion of muscle fibers formed with the participation of transplantedmyoblasts in cross
sections ofmuscle at day 7 of regeneration (nD 5). (C) The localization of transplanted ESCs expressing Green Fluoresent protein (GFP) in longitu-
dinal section of muscle at day 7 of regeneration (green - GFP, blue – chromatin, red – immunolocalization of laminin). (D) The localization of
mononucleated cells at muscle fiber isolated from skeletal muscle engrafted with ESCs expressing GFP analyzed at day 7 of regeneration (green
– GFP, red – immunolocalization of GFP using anti-GFP antibody, blue – immunolocalization of Myod1, yellow - chromatin). (E) Proportion of
ESCs expressing GFP in the population of mononucleated cells isolated from the muscle at day 7 and 14 of regeneration (nD 3). (F) Proportion
of ESCs expressing Myf5 in the population of GFP expressing ESCs (nD 3). FACS analysis of results is presented as mean§ standard deviation.
Student’s non-paired t-test was used for statistical analyses. Asterisk marks significant differences (P< 0.05).
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rarely formed aggregates and were mostly visible as a single
cells (Fig. 7C). Similar behavior characterized Sdf-1 treated
ESCs transplanted either into control or Sdf-1 treated
muscles. Silencing of Cxcr4 but not Cxcx7 expression led to
the decrease of ESCsmigration. As a result transplanted cells
were localized mostly in aggregates. FACS analysis allowed
us to verify the proportion of ESCs present within the mus-
cle at days 7 and 14 of regeneration. Generally, in the popu-
lation of mononucleated cells isolated from the regenerating
muscle we were able to detect between 0.32% and 1.65% of
ESCs at day 7 and only 0.08% – 0.64% of ESCs at day 14
(Fig. 7E). ESCs were identified on the basis of histone H2B-
GFP fluorescence. At day 7 of regeneration the proportion
of ESCs detectable within the muscles injected with saline
was 0.37%–1.44% and it reached 0.32%–1.65% in the
muscles treated with Sdf-1. At day 14 of regeneration the
proportion of ESCs was very low (less than 0.64%) and it
was comparable between control and Sdf-1 treated muscles.
Silencing of Cxcr4 or Cxcr7 expression did not decreased
the proportion of ESCs present in regenerating muscles
(Fig. 7E). Regardless of their localization, ESCs cells very
rarely expressed myogenic transcription factors, such as
Myod1, as demonstrated by immunolocalization (Fig. 7D).
At day 7 of regeneration up to 0.01% of GFP positive cells
i.e., ESCs isolated from the muscles expressed Myf5, as
shown by FACS analysis (Fig. 7F). At day 14 of regeneration
the proportion of Myf5 expressing ESCs reached 0.17%.
Sdf-1 did not change this proportion. Summarizing, Sdf-1
improved the ability of ESCs to migrate in injured muscle.
However, these cells only very rarely initiated myogenic
differentiation when transplanted into injuredmuscle.
Discussion
Our study shows that Sdf-1, acting via Cxcr4, increased pri-
mary myoblast, WJ-MSC, and ESCs ability to migrate in
vitro. Except increasing the expression of CD924 Sdf-1 also
impacts at the expression and activation of other proteins
engaged in cell adhesion and migration. Sdf-1 treatment
also resulted in the activation of FAK, i.e. non-receptor tyro-
sine kinase present in focal contacts composed of proteins
anchoring integrins with actin cytoskeleton (reviewed in ref.
40). Sdf-1 dependent FAK activation could be achieved by
stimulating both Cxcr4 and Cxcr7 receptors. Active FAK
kinase is a key component of many signal transduction
pathways (reviewed in ref. 43). However, from our point of
view, the role of FAK in the activation of cell motility is the
most important one (reviewed in ref. 44). Among such func-
tions of FAK could be its positive impact at the MMP-2 and
-9 (matrix metalloproteinases-2 and -9) expression and
activity influencing extracellular matrix degradation during
cells migration.45,46 Next, FAK signaling controls the forma-
tion and turnover of focal contacts46 and also activates Rho
GTPases leading to actin stress fiber formation.47 In our
study, Sdf-1 treatment of cells led also to the activation of
GTPases: Rac-1 and Cdc42 belonging to Rho GTPases fam-
ily. Importantly, activation of these proteins depended only
at Cxcr4. It was shown previously that Rac-1 mediates actin
polymerization in lamellipodia at the front ofmigrating cells
and Cdc42 induced actin polymerization in filopodia and
invadopodia.48
Our study also reveals the differences in cell signaling
mediated by Sdf-1 - Cxcr4 andCxcr7 pathways. Cxcr4 inter-
acts with Sdf-1 but Cxcr7 except Sdf-1 also binds chemokine
I-TAC (CXCL11) (reviewed in ref. 49). By silencing each of
these receptors we were able to distinguish which one is
involved in the regulation of certain genes. Thus, in ESCs
expression of CD9 is regulated via Sdf-1 activating Cxcr4,
but not Cxcr7, what was in agreement with our previous
results documenting Sdf-1 dependent expression of CD9 in
C2C12 myoblasts, bone marrow derived MSC, and ESCs.24
Here we showed that also expression of ADAM9 is induced
in ESCs by Sdf-1 in Cxcr4 dependent manner. The role of
ADAM-9 in the cell migration was previously documented
for keratinocytes and fibroblasts.50,51 Analysis of keratino-
cytes showed that ADAM-9 regulates cells migration by
interaction with integrin b1 and regulation of MMPs syn-
thesis.50 Thus, activation of FAK, Rac-1, and Cdc42, as well
as induction of CD9 and ADAM-9 expression, underlay the
ability of studied cells tomigrate.
We show that Sdf-1, acting viaCxcr4, increasedmyoblast
ability to migrate in vitro and participate in the formation of
new muscle fibers in vivo when transplanted intramuscu-
larly. The effect of Sdf-1 treatment was manifested better
when myoblasts and Sdf-1 were co-injected than when
myoblast were pre-treated with Sdf-1. On the other hand, it
was shown that the pre-incubation of myoblasts with bFGF
or Concanavalin A was shown to increase the efficiency of
myoblasts transplantation.52-54 The effect we observed was
also similar to that documented for other cell types, such as
mesoangioblasts, which pre-treatment with Sdf-1 or tumor
necrosis factor a (TNF-a) enhanced their delivery and led
to a complete reconstitution of skeletal muscles in mice that
serve as a mouse model of severe muscular dystrophy.55 In
our hands the pre-treatment of ESCs with Sdf-1 or co-injec-
tion of ESCs and Sdf-1 into skeletal muscles increased their
ability to migrate within the regenerating tissue. Previously,
we showed that ESCs pretreatment improved the ability of
ESCs to migrate and fuse with myoblasts in vitro.24 Since,
Sdf-1 increased the expression of CD9 in ESCs we postu-
lated that it might facilitate the fusion.24 Currently, we also
documented that Sdf-1 promoted migration of ESCs within
injured muscle and stimulated these cells to align in the
manner characteristic for fusing myoblasts. Unfortunately,
it did not affect the ESCs ability to initiate myogenic differ-
entiation and fusion withmyoblasts in vivo. However, it was
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previously shown that in order to inducemyogenic differen-
tiation of ESCs one has to either overexpress myogenic fac-
tors such as MyoD, Pax3 or Pax7 or treat the them with
precisely designed cocktail of factors (reviewed in ref. 33).
ESCs that were not subjected to such treatments fail to effec-
tively differentiate and fuse with myoblasts most probably
due to the fact that they do not initiate the expression of M-
cadherin or vascular cell adhesion molecule (V-CAM1) that
are also crucial for fusion.25
MSCs isolated from Wharton jelly (WJ-MSCs), as
well as adherent fraction of human umbilical cord blood
cells, i.e., the cells that constitute the subpopulation
enriched in MSCs, were shown by us to be able to follow
myogenic program both in vitro and in vivo.26,57 In our
hands WJ-MSCs were able to colonize injured skeletal
muscle and, with frequency of 5.3%, participate in the
formation of new muscle fibers. Pre-treatment of WJ-
MSCs with Sdf-1 did not impact their ability to form
new muscle fibers but significantly increased muscle
mass. Interestingly, in vitro these cells manifested myo-
genic potential and formed hybrid myotubes with
C2C12 myoblasts.26 Currently we documented that Sdf-
1 treatment induced migration of WJ-MSC in vitro.
However, this stimulation was not sufficient to improve
their participation in the muscle reconstruction. Our
result is in bright contrast to other study which showed
that MSCs isolated from rat or human bone marrow par-
ticipated in the formation of as many as 60–70% of new
muscle fibers and restored expression of dystrophin in
mdx mice muscles.57 Thus, MSCs isolated form varied
sources could differ in their myogenic potential.
Summarizing, Sdf-1 improved the ability of primary
myoblasts and ESCs to migrate within the injured muscle.
Moreover, injected intramuscularly Sdf-1 stimulated the
transplanted primary myoblasts to participate in the forma-
tion of new muscle fibers. Mechanisms controlling cells
migration activated by Sdf-1 rely at Cxcr4-dependent signal-
ing pathways leading to the activation of proteins engaged in
the focal contacts formation and actin polymerization, such
as FAK, Rac-1, and Cdc42, as well as the expression of CD9
andADAM-9. Sdf-1 - Cxcr7 interactions change the expres-
sion and activation of proteins engaged in cell migration,
however, these changes does not result in the alternation of
cell motility. Sdf-1 certainly improves migration of trans-
planted cells, however, fails to efficiently induce their myo-
genic differentiation. However, one has to remember that,
as we shown previously, it greatly impacts at the homing of
endogenous stem cells and by doing that improves muscle
regeneration.23,57
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kierownik projektu 
 
2015-2016 
„Rola Sdf-1 w migracji i różnicowaniu komórek macierzystych o potencjale miogenicznym- 
różnicowanie komórek macierzystych szpiku kostnego w niszy komórek satelitowych”   
Dotacja celowana na prowadzenie badań naukowych dla młodych naukowców, Wydział 
Biologii, 501/86-118617 
kierownik projektu 
 
2014 2017:  
„Znaczenie Sdf-1 i jego receptora Cxcr7 we wczesnych etapach różnicowania zarodkowych 
komórek macierzystych” 
PRELUDIUM 11, Narodowe Centrum Nauki, 2013/11/N/NZ3/00186 
kierownik projektu 
 
2014-2015:  
„Rola Sdf-1 w migracji komórek macierzystych pod błonę podstawną włókna mięśniowego”  
Dotacja celowana na prowadzenie badań naukowych dla młodych naukowców, Wydział 
Biologii, 501/86-107423,  
kierownik projektu 
 
2014-2017: 
„Molekularne mechanizmy i markery progresji płaskonabłonkowego raka sromu”  
SONATA BIS 3, Narodowe Centrum Nauki, 2013/10/E/NZ5/00663,  
Kierownik dr hab. Magdalena Kowalewska, Warszawski Uniwersytet Medyczny,  
wykonawca projektu  
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2013- 2015: 
„Participation of stem cells in muscle regeneration - cell signaling pathways” 
 POMOST, Fundacja na rzecz Nauki Polskiej, Pomost/2011-4/3,  
Kierownik: dr hab. Edyta Brzóska-Wójtowicz,  
wykonawca/stypendysta 
 
2012-2013: 
„Wpływ Sdf-1 na zdolność komórek macierzystych do fuzji. Określenie roli białka CD9”  
Dotacja celowana na prowadzenie badań naukowych dla młodych naukowców, Wydział 
Biologii, 501/86-104920,  
kierownik projektu 
 
2012-2014 
„Aktywacja mobilizacji komórek macierzystych ze szpiku kostnego do regenerujących mięśni” 
IUVENTUS PLUS, MNiSW, IP2011 004871,  
Kierownik: dr hab. Edyta Brzóska-Wójtowicz,  
wykonawca projektu 
 
2012 
„Stymulacja regeneracji mięśni szkieletowych - potencjalna rola cytokiny SDF-1” 
NAUKOWA FUNDACJA POLPHARMY, 2/VII/2008,  
Kierownik: dr hab. Edyta Brzóska-Wójtowicz,  
wykonawca projektu 
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Stypendia i nagrody: 
 
2016-2017 
Stypendium doktoranckie ETIUDA 20, Narodowe Centrum Nauki 2016/20/T/NZ3/00300 
„Różnicowanie komórek macierzystych szpiku kostnego w komórki o potencjale miogenicznym, 
wpływ niszy komórek satelitowych oraz chemokiny Sdf-1” 
w tym 3-miesięczny staż zagraniczny. Paryż, Instytut Cochin, Zakład Genetyki, Rozwoju i 
Fizjopatologii Mięśni Szkieletowych, opiekun Prof. Pascal Maire. 
 
2017-2018 
Stypendium START Fundacja na rzecz Nauki Polskiej, START 035.2017 
 
2012-2013 i 2015-2016 
Nagroda Rektora za Osiągnięcia Naukowe (nagroda zespołowa) 
 
2012-2013 i 2013-2014 
Stypendium dla najlepszych doktorantów Wydziału Biologii UW  
 
2013-2014, 2015-2016, 2016-2017 
Stypendium doktoranckie wypłacane z dotacji podmiotowej - projakościowej UW  
 
Nagroda specjalna za najlepszą pracę podczas V Ogólnopolskiej Konferencji Naukowej dla 
lekarzy, młodych naukowców i studentów „Postępy w Badaniach Biomedycznych” Warszawa, 
29 listopad 2014, prezentacja, „Sdf-1 wspomaga regenerację mięśni szkieletowych poprzez 
mobilizację endogennych komórek macierzystych.” 
 
 
 
 
 
 
 
  




